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ABSTRACT
Highly pathogenic avian influenza (HPAI) H5N1 is an emerging infectious
virus with a 60% fatality rate in humans. In the United States, a vaccine for H5N1
has been developed and stockpiled using FDA approved methods for seasonal
vaccines; however, the H5N1 vaccine was shown to be less immunogenic than
seasonal vaccines when evaluated in clinical trials. Adjuvants can be used to
enhance the immune response to antigens. For the studies described herein, a
lethal mouse model of H5N1 infection was utilized to examine the immune
response to the H5N1 vaccine with and without the addition of an alum adjuvant,
and these responses were compared to those induced by a seasonal influenza
vaccine. Mice that received the adjuvanted vaccine displayed significantly
reduced weight loss and increased survival following infection with H5N1
compared to mice that received the non-adjuvanted vaccine. Increased levels of
antibodies were detected in mice that received either the adjuvanted H5N1
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vaccine or the seasonal vaccine compared to mice that received the nonadjuvanted H5N1 vaccine. In vitro, both the seasonal and adjuvanted H5N1
vaccines more efficiently activated dendritic cells (DCs) when compared to the
non-adjuvanted H5N1 vaccine, as seen by enhanced levels of cytokine
production following treatment with the seasonal vaccine and an increase in costimulatory molecule expression following treatment with adjuvanted H5N1
vaccine. When treated with the adjuvanted H5N1 vaccine, DCs demonstrated
increased antigen uptake and intracellular processing compared to cells treated
with the non-adjuvanted vaccine. Pre-treatment with mannan or mannose
diminished cytokine production by DCs in a dose dependent manner following
seasonal, but not H5N1, vaccine treatment implicating C-type lectin receptor
activation as the mechanism by which the seasonal vaccine elicits protection.
These findings provide an explanation for attenuated DC function following H5N1
vaccination, and while an alum adjuvant is able to rescue H5N1 vaccine
immunogenicity it does so via a different mechanism than that utilized by
seasonal influenza vaccines. Furthermore, these studies provide insight into the
development of more immunogenic vaccines targeting HPAI.
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CHAPTER ONE: INTRODUCTION
Background
Influenza viruses cause annual global epidemics that result in three to five
million cases of severe illness and between 250,000 and 500,000 deaths
worldwide with approximately 36,000 deaths occurring in the United States [1, 2].
Symptoms include fever, cough, muscle and joint pain, severe malaise, sore
throat, and runny nose. Most affected people recover within a week, but as
mentioned above, severe illness and death can occur [2]. Seasonal epidemics
affect people of all ages, but high risk groups include children under the age of
two, adults age 65 and older, and people with chronic diseases or weakened
immune systems [2]. Vaccination is the most effective means of preventing
influenza infection, and it is estimated that 70%-90% of vaccinated healthy adults
are protected from the virus [2].
In addition to epidemics, influenza viruses can also cause occasional
pandemics. The most severe pandemic in the 20th century was the 1918
“Spanish Influenza” pandemic during which it is estimated that more than 50
million people died worldwide [1]. The most recent pandemic was the 2009 novel
H1N1 or “Swine Flu” pandemic. Circulation of the 2009 H1N1 virus resulted in a
pandemic because it consisted of a unique combination of influenza virus genes
that had never before been identified in animals or people, so pre-existing
immunity to the virus did not exist [3]. It is estimated that, globally, between
151,700 and 575,400 people died as a result of the 2009 H1N1 pandemic [4].
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Highly pathogenic avian influenza (HPAI) viruses are a type of influenza
virus with the potential to cause a pandemic [1]. As of April 26, 2013, the World
Health Organization has reported 628 confirmed cases of HPAI subtype H5N1
resulting in 374 deaths (59.5%) in 15 countries since 2003 [5]. Early symptoms of
disease include fever, cough, and dyspnea, while severe cases result in fast
progressing pneumonia, respiratory distress syndrome, damage to the central
nervous system, and multi-organ failure with death usually occurring within 10
days of symptom onset in fatal cases [6-8]. The potential for H5N1 to reach
pandemic levels arises if, as with the 2009 H1N1 pandemic, the HA or NA
segments from an HPAI virus were to be present in an influenza strain circulating
in humans to which there is no pre-existing immunity. Vaccines targeting HPAI
are being developed but they are not readily available, and early vaccines have
been shown to be ineffective unless supplemented with an adjuvant [9-11]. The
development of effective vaccines for HPAI reamins a priority.

Influenza Viruses
Influenza viruses are negative sense, segmented, single-stranded, RNA
viruses that belong to the family Orthomyxoviridae, and they are organized into
three genera commonly known as Influenza A, B, and C [7, 12-14]. Influenza A
viruses naturally occur in aquatic birds, and are the only influenza viruses that
infect birds. Influenza A viruses also infect a wider range of species including
humans, swine, and several other species of mammals [12, 14]. Influenza B
viruses infect humans and seals, and are less common and less genetically
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diverse than Influenza A viruses [14-16]. Influenza C viruses infect humans and
pigs, and while they may cause isolated epidemics, they are less common than
Influenza A and B viruses and result in a more mild form of disease [2, 14, 1720]. Seasonal epidemics are caused by Influenza A and B viruses, while
pandemics are the result of the introduction of a novel Influenza A subtype into
the population for which there is limited or no pre-existing immunity [15, 21].
The influenza viral genome is organized into eight segments that encode
up to 13 proteins, including surface glycoproteins, polymerase proteins, structural
proteins, and non-structural proteins [7, 14]. The genome is surrounded by a lipid
envelope derived from the plasma membrane of the infected host cell. The
hemagglutinin (HA) and neuraminidase (NA) glycoproteins radiate outward from
the lipid envelope and are the major antigenic proteins of the virus, against
which, neutralizing antibodies are produced [14] (Figure 1). The HA and NA
proteins are also the most variable proteins due to the lack of proof-reading by
the viral polymerase which results in mistakes in genome copying and frequent
mutations. This concept is referred to as antigenic drift and is the reason a new
influenza vaccine is needed every year [22]. Influenza viruses are also subject to
antigenic shift. Antigenic shift results when new HA and NA proteins enter the
human population as a consequence of genetic reassortment between an
influenza virus circulating in humans and an influenza virus circulating in another
species such as pigs or birds [22]. Antigenic shift often results in a pandemic
strain of influenza as the HA or NA segment of the new virus has most likely not
circulated in humans before. [22].

3

Influenza A viruses are divided into subtypes based on the antigenic
properties of the HA and NA proteins as determined by phylogeny [13, 14, 21].
As of 2012, 17 HA and 9 NA subtypes have been identified and characterized [7,
13, 23]. The subtypes H3N2 and H1N1 circulate in humans as the seasonal
viruses, along with Influenza B. Influenza B viruses are not divided into subtypes,
but are further classified into strains [20]. HPAI viruses are limited to the H5 and
H7 subtypes, but not all H5 and H7 viruses are highly pathogenic. Some are
designated as low pathogenic avian influenza (LPAI) viruses [12]. There is a
standard nomenclature system for influenza viruses that consists of the antigenic
type (A, B, or C), the host of origin (duck, equine, swine), geographical origin,
strain number, and year of isolation. The host of origin is omitted for human
isolates. For Influenza A viruses, this nomenclature is followed by the antigenic
description in parentheses [20, 24]. For example, A/Vietnam/1203/2004 (H5N1)
is an Influenza A virus isolated from a human in Vietnam in 2004.

Highly Pathogenic Avian Influenza
All Influenza A viruses, including HPAI viruses, occur naturally in wild
aquatic birds; however, they are occasionally transmitted to other hosts, such as
domestic poultry and mammals, causing transient infections and occasional
deaths [7, 25, 26]. On rare occasions, when influenza viruses are transmitted
from aquatic birds to other species, continuous infections are established
resulting in permanent influenza lineages in those hosts such as the seasonal
influenza viruses that affect humans [25]. Therefore, HPAI viruses do not
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normally infect humans, but rare cases do occur. Most human infections with
HPAI are the result of close contact with infected poultry. Human-to-human
transmission is rare, limited, and unsustainable [26]. Reports of human-to-human
transmission include isolated household clusters of infection and a case where a
child transmitted the infection to her mother [27, 28].
The first H5N1 virus outbreak in humans occurred in 1997 in Hong Kong.
During this time, the virus was first identified in a 3-year-old boy who died in a
Hong Kong hospital from Reye’s syndrome, acute influenza pneumonia, and
respiratory distress syndrome. The outbreak resulted in a total of 18 confirmed
cases resulting in 6 deaths [29-33]. Following the 1997 outbreak, avian influenza
was not detected in humans again until 2003 [33]. The new cases of H5N1 were
identified in a family of five from Hong Kong who had been visiting mainland
China, and who had been in close contact with live chickens. Three of the family
members became ill and two died from the disease [33]. By July 16, 2004, the
HPAI epidemic had affected eight countries and resulted in at least 23 deaths
[34]. Since 2003, human cases of H5N1 have persisted with 628 confirmed
cases resulting in an approximate 60% fatality rate as of April 26, 2013 [5]. In
2013, a novel HPAI H7N9 virus outbreak began to affect China [35, 36]. This is
the first time an influenza A virus with an N9 subtype has been documented in
humans [36]. The first cases were reported in February 2013, and as of May 30,
2013, 132 cases have been confirmed resulting in 37 deaths (28%) with new
cases being reported daily [37]. HPAI viruses therefore remain a current and
future threat to public health.

5

Influenza Vaccines
Vaccination is the most effective means for the prevention and control of
infectious diseases, including influenza [38, 39]. Vaccination against influenza
prevents 70%-90% of influenza specific illness in healthy adults, as well as,
decreases severe illness and complications in the elderly by 60% and deaths by
80% [2]. In the United States, there are two types of influenza vaccines
approved for use: 1) the injectable inactivated trivalent influenza vaccine (TIV)
approved for use in people aged 6 months and older, and 2) the intranasal live
attenuated influenza vaccine (LAIV) approved for use in people aged 2 to 49.
Neither the TIV nor the LAIV utilizes an adjuvant [40-43]. The TIV is the
traditional influenza vaccine, and remains the most widely used [41]. Inactivated
influenza vaccines were first shown to be effective during World War II, and since
then, they have been repeatedly shown to be effective [44-48]. The TIV influenza
vaccine has been recommended for use since 1960; however, its use possesses
some limitations including lower immunogenicity in the very young and the
elderly, and, since it is administered intramuscularly, it needs to be given by
trained personnel [41, 43].
The LAIV vaccine was licensed for use in 2003 by the United States Food
and Drug Administration (USFDA) [43]. It has some advantages over the TIV as
it has been shown to have higher immunogenicity compared to the TIV and can
be administered intranasally [40, 41]. Also, whereas the TIV only induces a
systemic immune response, the LAIV induces both a systemic and mucosal
immune response [41]. The LAIV contains live attenuated virus that is cold-
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adapted, which means it can only replicate and grow at temperatures less than
25°C. This adaptation should prevent the virus from growing in the lungs and
respiratory tract following vaccination; however, since the vaccine does contain
live virus, there are safety concerns, especially in people with weakened immune
systems [41, 42]. Both the TIV and the LAIV are trivalent vaccines using the
same vaccine strains [40, 41]. Herein, focus will be placed on the TIV.
Influenza vaccine production is a standardized process, and the complete
manufacturing process takes about five to six months [49, 50]. The World Health
Organization’s Global Influenza Surveillance Network, consisting of five influenza
centers in London, Tokyo, Melbourne, Memphis, and Atlanta, continuously
monitors circulating strains of influenza [49, 50]. Vaccine strains are chosen
based on the circulating viruses and consist of three different influenza viruses,
hence the trivalent nature of the vaccine. Two of the three viruses included in the
annual vaccines are Influenza A viruses, an H3N2 and an H1N1, while the third
virus is an Influenza B strain [49, 51].
Following selection of the vaccine strains, the viruses are grown in
fertilized chicken eggs along with A/Puerto Rico/8/1934 (H1N1) (PR8), a
standard laboratory virus that grows quickly and efficiently in eggs. As the viruses
grow and replicate, reassortment occurs in which the eight segments from each
virus recombine forming hybrid viruses that contain a mixture of segments from
each strain. The target viruses contain the HA and NA segments from the viruses
chosen for the vaccine and all other segments from PR8. Antibodies against the
HA and NA segments from PR8 can be included during the culture process to
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help select for the target viruses (Figure 2). It takes approximately three weeks to
prepare the hybrid viruses. Once the hybrid viruses have been generated, they
are verified at one of the influenza surveillance centers to make sure they are
safe, can grow in eggs, express the correct HA and NA proteins, and to ensure
that they can produce a robust immune response. The vaccine strains are then
distributed to vaccine manufacturers [49, 50].
After receiving the vaccine strains from the influenza surveillance centers,
the manufacturers must mass produce the viruses in order to have a large
enough quantity to generate an adequate amount of vaccine. The viruses are
again grown in fertilized chicken eggs, and it takes thousands of eggs to produce
a sufficient amount of virus [50]. The viruses are inactivated, or “killed”, with
formaldehyde, followed by purification in a linear sucrose density gradient
solution using continuous flow centrifugation. The viruses are then chemically
disrupted using Octylphenol Ethoxylate (Triton® X-100) producing a split virus. A
split virus consists of pieces of the virus rather than an intact viral particle. The
split virus is further purified so that it contains only the HA and NA proteins, thus
designating it a subunit vaccine. The viral proteins are then suspended in sodium
phosphate-buffered isotonic sodium chloride solution creating the final vaccine
preparation [52]. Each batch, or lot, of the vaccine is tested for sterility and
amount of protein, or antigen. The vaccine then undergoes clinical trials for
safety evaluation, and to show that it performs as expected. Clinical trials are not
required in all countries as previous studies on annual influenza vaccines were
performed and the assumption is that the new vaccines will behave similarly. The
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vaccine must then be approved by regulatory agencies before it can be
introduced into the national immunization program [50].
An inactivated subunit vaccine targeting the HPAI strain
A/Vietnam/1203/2004 (H5N1) has been developed using the methods described
above, and 20 million doses of this vaccine have been stockpiled in the United
States in case of a pandemic [53]. Despite the ability of seasonal influenza
vaccines and the 2009 H1N1 pandemic vaccine to stimulate the production of
protective antibody titers, the H5N1 vaccine was shown to have low
immunogenicity [2, 11, 44-48]. Vaccine efficacy in humans is determined by the
production of antibodies against HA with titers of greater than 1:40 deemed
protective. When evaluated in clinical trials, 70% of Fluzone® 2009/2010 TIV
vaccine recipients developed protective antibody titers, and 95%-100% of
Fluzone® 2009 H1N1 pandemic TIV vaccine recipients developed protective
antibody titers [47, 48]. When the H5N1 subunit vaccine was evaluated in clinical
trials, only 22% of recipients developed protective antibody titers (Figure 3) [11].

Alum Adjuvants
Adjuvants are substances that can be added to vaccines in order to
augment the immune response. The term adjuvant comes from the Latin word
“adjuvans” which means “to help” [54, 55]. The use of adjuvants was first
exploited by William Coley, who used bacterial components to treat cancer
patients, and by Ramon and Glenny who used tapioca and aluminum hydroxide
along with diphtheria and tetanus toxins to enhance responses in horses and
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guinea pigs [54]. The adjuvant alum, which is based on aluminum salts, is the
most widely used adjuvant worldwide, and until recently was the only adjuvant
approved for use in the United States [54-57]. The adjuvant AS04, which is a
combination of monophosphoryl lipid A (MPL), a derivative of the bacterial cell
wall component lipopolysaccharide (LPS), and alum, was approved for use in
2009 for the Cervarix vaccine targeting human papilloma virus (HPV) [56, 58].
Other vaccines licensed for use in the United States that contain alum include
those for diphtheria, tetanus, and pertussis (DTaP), hepatitis A and B,
pneumonia, anthrax, and rabies. Approved influenza vaccines do not contain an
adjuvant [59].
It is not fully understood how adjuvants function, and they have been
shown to act in many different ways to enhance immunity to an antigen. The term
antigen refers to a foreign substance that induces an immune response [60].
Many adjuvants seem to stimulate antigen presenting cells (APCs) such as
dendritic cells (DCs) enhancing maturation, migration, antigen presentation, and
the expression of co-stimulatory molecules which leads to improved responses of
T and B cells [54]. Alum has been shown to work in several different ways
leading to confusion and controversy surrounding its mechanism of action [54-56,
61]. In vaccines containing alum, antigens are adsorbed onto the aluminum salts
and the mixture is injected intramuscularly creating a nodule at the site of
injection. The original theory behind the mechanism of action of alum, which is
still widely believed, is that alum acts as an “antigen depot” by slowly releasing
antigen to the immune system and prolonging exposure [54-57]. One study
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showed, however, that removal of the alum nodule one week following
vaccination had no effect on the antibody response generated against the
pathogen [62], while another study demonstrated that adsorption of the antigen
to alum was not required for the ability of alum to enhance the immune response
[63]. If the antigen is not adsorbed to alum, then prolonged exposure at the depot
is not taking place.
Another mechanism of action demonstrated for alum is the activation of
the NLRP3 (also known as NALP3) inflammasome immune complex [64]. The
NLRP3 inflammasome complex is a molecular platform consisting of the proteins
NLRP3, ASC, and pro-caspase-1. Activation of the inflammasome in turn leads
to activation of caspase-1. Activated caspase-1 then proteolytically cleaves proIL1β and pro-IL18 resulting in the secretion of their biologically active forms, the
pro-inflammatory cytokines IL1β and IL-18, which induce an anti-microbial
response [65]. NLRP3 inflammasome activation requires two signals, and alum
has been shown to provide the second signal which directly activates NLRP3.
The first signal is provided by endogenous or microbial antigens that activate NFκB and induce NLRP3 expression [64, 65]. Antigens that provide the first signal
include lipopolysaccharide (LPS), muramyl dipeptide (MDP), bacterial RNA, the
dsRNA analog polyI:C, and microbial lipopeptide [65]. While alum has been
shown to activate the NLRP3 inflammasome pathway, other studies have
demonstrated that alum can enhance the immune response in the absence of
inflammasome activation [66].
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A third means by which alum has been shown to function as an adjuvant
is through increasing antigen uptake by DCs [67, 68]. To this end, alum was
shown to interact directly with lipids on the cell surface of DCs, specifically
sphingomyelin and cholesterol, promoting lipid sorting in the plasma membrane.
The lipid sorting activated an endocytic response which led to increased antigen
uptake. In addition to antigen uptake, the lipid sorting also triggered Syk and
phosphoinositide 3-kinase (PI3K) signaling pathways inducing an immune
response [67, 68]. Interestingly, the study demonstrated that while alum
facilitates increased antigen uptake, the adjuvant itself does not enter the cell,
rather it remains at the plasma membrane [67, 68].
Regardless of the mechanism, alum adjuvants are known to induce robust
antibody responses, and have been shown to promote a T-helper 2 (TH2) type
immune response rather than a T-helper 1 (TH1) type immune response, referring
to the subset of CD4+ T cells being activated [56, 57, 64]. TH2 responses are
associated with IL-4 production and the generation of IgG1 and IgE antibodies,
whereas TH1 responses are associated with the production of high levels of IFNγ,
the secretion of IL-12, and the generation of IgG2 antibodies [56, 57, 64]. TH1
responses are known to operate through Toll-like receptors (TLRs,) and it has
been demonstrated that alum does not directly activate TLRs [56].

The Immune Response to Vaccination
The immune response to vaccination is initiated by the recognition of
foreign antigen by innate immune cells such as dendritic cells (DCs),
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macrophages, and neutrophils. DCs and macrophages function as antigen
presenting cells (APCs) [61, 69], and DCs in particular, have been shown to be
important for the recognition of vaccine antigens, which they detect via germlineencoded pathogen receptors known as Pattern Recognition Receptors (PRRs)
[70]. PRRs recognize conserved microbial structures called Pathogen Associated
Molecular Patterns (PAMPs) found on a variety of microbes, such as bacteria,
viruses, yeast, fungi, protozoa, and parasites [61, 69, 71]. PAMPS include, but
are not limited to, peptidoglycans, lipopolysaccharides, and viral RNA and DNA
[61, 69]. Several classes of PRRs have been identified and include: Toll-like
receptors (TLRs), nucleotide-oligomerization domain (NOD)-like receptors
(NLRs), and C-type lectin receptors (CLRs) which recognize a variety of
pathogens; as well as retinoic acid-inducible gene-1 (RIG-1)-like receptors
(RLRs) which recognize viral nucleic acids [39, 72-75].
TLRs are the most widely studied PRRs [69]. Eleven TLRs have been
identified in humans and 13 TLRs have been identified in mice, with TLRs 1-9
being conserved between humans and mice [69, 71]. TLRs 1, 2, 4, 5, and 6 are
expressed on the cell surface and recognize PAMPs from bacteria, fungi, and
protozoa. TLRs 3, 7, 8, and 9 are located in cellular endosomal compartments
and recognize bacterial and viral nucleic acids [69]. Influenza viruses are
recognized by TLR3, which senses dsRNA, and TLR7/8 which senses ssRNA
[76]. TLRs are type 1 transmembrane glycoproteins that consist of extracellular
leucine rich repeats (LRRs) important for pathogen recognition, and a
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cytoplasmic Toll/interleukin-1 receptor (TIR) domain required for signaling [69,
77].
NLRs recognize cytosolic PAMPs as well as host derived molecules
associated with danger or stress referred to as Danger Associated Molecular
Patterns (DAMPs) [69, 78]. DAMPs include molecular crystals, reactive oxygen
species, potassium efflux, and ATP [78]. Twenty three NLRs have been identified
in humans and approximately 34 have been identified in mice. NOD1 and NOD2
are among the most well studied members of the NLR family [79]. Additionally,
NLRP1, NLRP3, and NLRC4 are NLR family members that form inflammasomes
[74]. Structurally, NLRs consist of 3 domains: a C-terminal leucine rich repeat
(LRR) domain which is important for the recognition of PAMPs and DAMPs; an
N-terminal Caspase Recruitment Domain (CARD) important for signaling; and a
centrally located nucleotide-binding oligomerization domain (NBD or NACHT)
also required for signaling [69, 79].
CLRs are a large superfamily of proteins that contain one or more C-type
lectin-like domain (CTLD), and they are divided into 17 groups based on
functional and structural characteristics [72, 74]. The term C-type lectin comes
from the original observation that their activities were calcium dependent;
however, some CLRs have since been identified to function in a calcium
independent manner [72]. Structurally, CLRs contain at least one carbohydrate
recognition domain (CRD); however, not all CLRs bind carbohydrates [72, 73].
CLRs exist as both transmembrane and cytosolic receptors. Those that function
as PRRs are the transmembrane receptors which recognize carbohydrates,
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specifically mannose, fucose, and glucan structures. With carbohydrates as their
ligands, CLRs recognize most types of human pathogens [72, 73]. There are two
main ways in which CLRs induce signaling cascades. The first is through adaptor
molecules that contain immunoreceptor tyrosine-based activation motifs (ITAMs),
such as FcRγ chains. The second is through the activation of protein kinases or
phosphatases that interact, either directly or indirectly, with the cytoplasmic tails
of the receptors [73, 74]. CLR family members include DC-SIGN, Dectin-1,
Dectin-2, Mincle, and CLEC5A [73, 74].
In general, the activation of PRRs is followed by signaling cascades which
lead to the activation of transcription factors, such as NF-κB, followed by the
regulation of cytokine gene expression and the secretion of pro-inflammatory
cytokines such as IL-6, IL-12, IL-1β, and TNF-α [39, 72-75, 77, 79, 80]. Following
recognition, antigens are internalized by DCs and degraded into small peptides.
The peptides are processed and presented to T cells via major histocompatibility
complex (MHC) class I or class II molecules which interact with the T cell
receptor (TCR) on naïve T cells [61, 70]. Activated DCs also up-regulate the
expression of co-stimulatory cell-surface molecules such as CD80/CD86 and
CD40, which bind their cognate receptors CD28 and CD40L, respectively, on the
surface of naïve T cells [61, 70]. Antigen-MHC interaction with the TCR, together
with co-stimulatory molecule interaction with cognate receptors, provides a dual
signal leading to the activation of naïve T cells.
Activated T cells produce cytokines such as IL2, IL-4, IL-7, IL-15, and IFNγ which enhance T cell proliferation (clonal expansion) and survival, have
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important anti-microbial functions, and influence B cell differentiation and
antibody production [60, 61, 70]. T cells are categorized based on their function,
with the most well characterized populations consisting of helper T cells (CD4+)
and cytotoxic T cells (CD8+) [60]. Cytotoxic T cells eliminate infected cells, while
helper T cells assist macrophages in the elimination of pathogens and also
stimulate B cells responses and antibody production [60, 70].
B cells are the only type of cells that produce antibodies. Antibodies
recognize microbial antigens, bind to the microbe, block the ability of the microbe
to infect host cells, and target the microbe for destruction by various mechanisms
[60]. B cells secrete five different types of antibodies in response to different
types of pathogens, and each class of antibody has a distinct structure, function,
and location within the body. The different classes of antibodies are referred to
as isotypes and consist of IgG, IgE, IgM, IgA, and IgD, with the prefix “Ig”
referring to immunoglobulin, another term for antibody indicative of protein
structure [60, 81].
IgG is the main class of antibody found in the serum and is important for
the response to viruses and bacteria, and it is the only antibody isotype that can
cross the placental barrier providing passive immunity to the fetus. There are four
subclasses of IgG in humans (IgG1, IgG2, IgG3, and IgG4) [60, 81]. Influenza
vaccines, as with most vaccines, provide protection by inducing antibody
responses, specifically IgG responses [39, 82].
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Purpose of Study
Highly pathogenic avian influenza viruses are an emerging threat to public
health with the potential to cause a pandemic. While a split virion subunit vaccine
has been developed according to the process used for seasonal vaccines, it
demonstrated low immunogenicity in clinical trials. The immunological
mechanisms behind vaccination are incompletely understood. This dissertation
includes the results from two original studies that examined differences in the
immune response to an inactivated subunit seasonal vaccine and an inactivated
subunit vaccine for H5N1 with and without the addition of an alum adjuvant. A
better understanding of the mechanism by which vaccines confer protection
could lead to the development of more effective vaccines.
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Figure Legends
Figure 1. Cartoon representation of an influenza virus. The influenza viral
genome is comprised of eight segments of single-stranded RNA surrounded by a
lipid envelope. The hemagglutinin (HA) and neuraminidase (NA) glycoproteins
radiate outward from the lipid envelope.

Figure 2. Influenza subunit vaccine manufacturing process. A. The influenza
virus that the vaccine will target (in this example, A/Vietnam/1203/2004 (H5N1)
(VN1203)) is grown in fertilized chicken eggs along with the influenza virus
A/Puerto Rico/8/1934 (H1N1) (PR8). While replicating in the eggs, genome
segments from the two viruses will reassort forming hybrid viruses that contain
segments from both viruses. The target virus for the vaccine will contain the HA
and NA segments from VN1203 and all other segments from PR8. Antibodies
against the HA and NA segments from PR8 can be included in the culture
process to facilitate selection of the target virus. B. Once the target virus has
been generated, it is again grown in fertilized chicken eggs. The virus is then
harvested from the eggs and inactivated or “killed” with formaldehyde. Following
purification in a linear sucrose gradient, the virus is chemically disrupted
producing a split virus. The virus is then further purified so that it contains only
the HA and NA proteins, which are then suspended in sodium phosphatebuffered isotonic sodium chloride solution creating the final vaccine preparation.
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Figure 3. Antibody titers following influenza vaccination in human clinical
trials. When tested in human clinical trials, 70% of Fluzone® 2009/2010 TIV
vaccine recipients and 95%-100% of Fluzone® 2009 H1N1 pandemic vaccine
recipients developed protective antibody titers greater than 1:40. Only 22% of
H5N1 inactivated subunit vaccine recipients developed protective antibody titers
greater than 1:40. This graph is adapted from Plennevaux, E., et al., Lancet,
2010 [47], Xie, H., et al., PLosONE, 2011 [48], and Treanor, J.J. et al., New
England Journal of Medicine, 2006 [11].

26

Figures
Figure 1

27

Figure 2

28

Figure 3

29

CHAPTER TWO:
Attenuated antigen presenting cell function in BALB/c mice following HPAI
vaccination results from impaired C-type lectin receptor signaling

Sarah E. Vaughan1,2, Heather W. Stout-Delgado1, Zemmie E. Pollock1, Jennifer
R. Plourde1,2, John A. Pyles1, Bridget S. Wilson2, and Kevin S. Harrod1,#

1

Infectious Diseases Program, Lovelace Respiratory Research Institute,

Albuquerque, NM, 87108

2

Biomedical Sciences Graduate Program, University of New Mexico,

Albuquerque, NM, 87131

# Email:kharrod@lrri.org

Conceived and designed experiments: SEV, HWS, BSW, KSH. Performed the
experiments: SEV, HWS, ZEP, JRP, JAP. Analyzed the data: SEV, HWS, KSH.
Wrote the paper: SEV, KSH.

30

Abstract
Highly pathogenic avian influenza (HPAI) H5N1 has an approximate 60%
fatality rate in humans. In the United States, a vaccine for H5N1 has been
manufactured and stockpiled using FDA approved methods for seasonal
influenza vaccines. In clinical trials, the H5N1 vaccine was shown to be less
immunogenic compared to seasonal vaccines. Herein, we utilized a BALB/c
mouse model to elucidate the underlying immune mechanisms by which
immunization with the HPAI vaccine results in attenuated immunogenicity. Mice
that received the seasonal vaccine produced a robust neutralizing antibody
response whereas no neutralizing antibodies were detected following HPAI
vaccination. Bone marrow derived dendritic cells (BMDCs) cultured with the
seasonal vaccine produced significantly higher levels of the pro-inflammatory
cytokines IL-6, IL-12, and TNF-α compared to those treated with the H5N1
vaccine, indicating increased antigen presenting cell (APC) activation. Neither
vaccine stimulated Toll-like receptors nor NOD-like receptors; therefore, as Ctype lectin receptors have been implicated as a class of pattern recognition
receptors involved in innate immunity and immunization their involvement was
examined. Pre-treatment with mannan or mannose diminished cytokine induction
by DCs in a dose dependent manner following seasonal but not HPAI vaccine
treatment, suggesting a role for C-type lectin receptors in DC activation by the
seasonal influenza vaccine. BMDCs pre-treated with the H5N1 vaccine displayed
decreased cytokine production following treatment with either the seasonal
vaccine or mannan suggesting that the HPAI vaccine is binding to the receptors
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but not inducing a signaling cascade. These findings provide a novel role for Ctype lectin receptors in influenza vaccination, and a potential mechanism for
attenuated APC function following H5N1 vaccination and may explain the
decrease in immunogenicity of the currently approved HPAI vaccine.
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Introduction
Highly pathogenic avian influenza (HPAI) H5N1 is an emerging infectious
virus associated with occasional illness and death in humans. Recent outbreaks
have occurred in Cambodia, Bangladesh, China, and Egypt [1, 2]. So far, in 2013
documented cases have resulted in a 78% mortality rate, with the overall
mortality rate being slightly lower at 60% [1]. Symptoms in affected people
include fast progressing pneumonia, respiratory distress syndrome, damage to
the central nervous system, and multi-organ failure, and death usually occurs
within 10 days of symptom onset in fatal cases [3, 4]. The high lethality rate and
occasional infection in humans make an H5N1 pandemic feasible; therefore, an
effective vaccine targeting H5N1 is a high priority, especially in affected countries
[5-7].
As part of the pandemic preparedness plan, the United States has
stockpiled 20 million doses of an inactivated subunit vaccine targeting H5N1 [8].
The H5N1 vaccine is manufactured employing the same techniques used to
generate seasonal influenza subunit vaccines [9]. In clinical trials, seasonal
influenza subunit vaccines have demonstrated the ability to produce protective
antibody titers, which are considered to be greater than 1:40, in the majority of
recipients. One study demonstrated that 70% of recipients developed protective
titers to the 2009/2010 seasonal vaccine, and another showed 95%-100% of
recipients developed protective titers to the 2009 novel H1N1 influenza vaccine
[10, 11]. When the H5N1 vaccine was tested in clinical trials, however, only 22%
of recipients developed protective antibody titers [12].
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The use of vaccines is one of the most effective means for preventing
infectious diseases [13]. Recognition of foreign antigen by innate immune cells,
such as dendritic cells (DCs), initiates the immune response to vaccination. DCs
function as antigen presenting cells (APCs) by responding to, processing, and
presenting antigen to T cells [14]. DCs detect antigen via germline-encoded
pathogen receptors known as pattern recognition receptors (PRRs). PRRs
recognize conserved molecular structures found on groups of pathogens referred
to as pathogen-associated molecular patterns (PAMPs) [15, 16]. PRRs include
Toll-like receptors (TLRs), nucleotide-oligomerization domain (NOD)-like
receptors (NLRs), and C-type lectin receptors (CLRs) which recognize a variety
of pathogens, as well as retinoic acid-inducible gene-1 (RIG-1)-like receptors
(RLRs) which recognize viral nucleic acids [13, 15-18]. The activation of PRRs is
followed by signaling cascades which lead to the activation of transcription
factors and the subsequent regulation of cytokine gene expression, and this
process helps shape effective adaptive immune responses [13, 15-18].
The specific mechanisms by which vaccines induce protective immunity
remain to be elucidated [13]. Herein, we utilized a vaccination model in BALB/c
mice to study the mechanism by which the seasonal influenza vaccine elicits a
more robust antibody response than the H5N1 vaccine. We show that treatment
with the seasonal vaccine results in increased total and functional antibody
production in BALB/c mice. In vitro, BMDCs treated with the seasonal vaccine
produced higher levels of pro-inflammatory cytokines compared to cells treated
with the H5N1 vaccine; however, APC activation was not via TLRs or NLRs. The
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seasonal vaccine stimulated CLRs to induce pro-inflammatory cytokine
production, whereas the H5N1 vaccine bound CLRs but did not initiate APC
activation. These findings describe a novel role for C-type lectin receptors in
influenza vaccination, as well as, a potential mechanism for attenuated APC
function following H5N1 vaccination providing insight into the development of
more immunogenic vaccines targeting HPAI.

Materials and Methods
Mice
Male BALB/c mice, aged six to eight weeks, were purchased from the
National Cancer Institute at Frederick (NCI-Frederick, Bethesda, MD), and were
held for 21 days for quarantine and acclimation. Mice were housed four per cage
in microisolator cages under identical husbandry conditions and fed certified
commercial feed. All animal studies were approved by the Lovelace Respiratory
Research Institute Internal Animal Care and Use Committee.

Vaccines
The following reagents were obtained through the National Institutes of
Health (NIH) Biodefense and Emerging Infections (BEI) Research Resources
Repository, NIAID, NIH: Monovalent Influenza Subvirion Vaccine,
rg/A/Vietnam/1203/2004, NR-4143 and Fluzone® Influenza Virus Vaccine, 20092010 Formula, NR-19879 at concentrations of 30ug/ml hemagglutinin protein.
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Vaccines were diluted to 0.6ug/ml HA protein within 0.05ml physiological saline
immediately prior to vaccination.

Viruses
Influenza virus A/Brisbane/59/2007 subtype H1N1 was obtained from the
Centers for Disease Control and Prevention (Atlanta, GA) as low-passage stock.
The virus was passaged once in 10-day old embryonated chicken eggs to
generate the master stock and then twice in eggs and once in Madin-Darby
Canine Kidney (MDCK) cells to generate the virus for all subsequent uses.
Aliquots of 0.5ml to 1ml were stored at -80°C. After storage, the virus was
determined to have a concentration of 4.85 x 106 tissue culture infectious dose
50 (TCID50).
Influenza virus A/Vietnam/1203/2004 (VN1203) subtype H5N1 was
obtained from the Centers for Disease Control and Prevention (Atlanta, GA) as
low-passage stock. The virus was passaged once in 10-day old embryonated
chicken eggs to generate the master stock and then twice in eggs to generate
the virus for all subsequent uses. Aliquots of 0.5ml to 1ml were stored at -80°C.
After storage, the virus was determined to have a concentration of 1.4 x 10 8
plaque forming units (pfu/ml), 5.8 x 108 50% tissue culture dose (TCID50/ml), and
1 x 108 50% egg infectious dose (EID50/ml). Influenza A/Vietnam/1203/2004 is a
Risk Group 3 pathogen and all experiments involving this virus were carried out
in a Biosafety Level 3 (BSL 3) containment facility at the Lovelace Respiratory
Research Institute and approved by the Institutional Biosafety Committee.
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Vaccination and Serology
Mice (n = 6 per group, except seasonal IM where n = 18 as this group was
performed separately) were given either a subcutaneous (SC) or intramuscular
(IM) injection of 0.6ug seasonal influenza or HPAI vaccine in the gastrocnemius
muscle. Control animals received injections of 0.05ml physiological saline either
IM or SC. Blood for serum was collected in serum separator collection tubes 3
weeks following vaccination by cardiac puncture, and incubated at room
temperature for 30 minutes before centrifugation at 2500rpm for 10 min. Serum
was collected and kept at -20°C until analyzed. The neutralization assay was
modified from previously described procedures [19]. Briefly, serum samples were
treated with receptor-destroying enzyme (RDE (II)), (Enka-Seiken, Tokyo,
Japan), at a ratio of 1:1 followed by heat inactivation at 56°C for 45 minutes. The
serum samples were incubated with 2 x 103 TCID50 A/Brisbane/59/2007 or
A/Vietnam/1203/2004 at 37°C for one hour. After incubation, MDCK cells plated
in 96 well plates were inoculated in triplicate with the samples using a 2-fold
dilution and incubated at 37°C for three days. The plates were then scored for
cytopathic effect (CPE), and neutralizing antibody titers were determined as the
highest serum dilution at which no CPE occurred.
Total vaccine specific IgG was determined by ELISA using modified
previously described techniques [20]. Briefly, 96-well plates were coated with
1ug/ml seasonal or H5N1 vaccine in coating buffer (eBioscience, San Diego, CA.
Catalog # 00-0044-59) and incubated overnight at 4°C. Following incubation,
plates were washed with 1x PBS containing 0.05% Tween® 20 (Sigma-Aldrich,
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St. Louis, MO). Plates were blocked with 1x assay diluent (eBioscience. Catalog
#00-4202) for 1 hour at room temperature before incubation with serum samples
from vaccinated mice, diluted 1:10,000 in assay diluent, for 2 hours at room
temperature. Following additional washes, total vaccine specific IgG was
determined by incubation with horse anti-mouse IgG (H & L) conjugated to HRP
(Cell Signaling Technology, Danvers, MA) at a 1:250 dilution in assay diluent for
1 hour at room temperature. Following a wash step, TMB substrate solution
(eBioscience) was added to develop color, and 2N H2SO4 was added to stop the
reaction. Plates were read at 450nm absorbance, and optical density (OD)
values are reported.

Primary Bone Marrow Cell Isolation and Culture
Bone marrow cells were collected and cultured using previously described
methods [21]. Briefly, bone marrow cells were isolated from the femurs and tibiae
of BALB/c mice and cultured in complete RPMI media (Invitrogen, Carlsbad, CA)
containing 10% FBS (Invitrogen), 1x penicillin/streptomycin (Invitrogen), and
25ng/ml GM-CSF (Cell Signal Technology, Danvers, MA) for 5-7 days at 37°C
with 5% CO2.

Cytokine Analysis
BMDCs in complete RPMI media were treated with either seasonal
influenza vaccine or H5N1 vaccine at a concentration of 0.6ug/ml (HA protein),
100ng LPS-EB (InvivoGen, San Diego, CA), or media alone for 24 hours. Cell

38

culture supernatants were analyzed for IL-6, IL-12, and TNF-α production using
ELISA kits purchased from eBioscience according to the manufacturer’s
instructions.

TLR/NLR Expression Assay
THP1-XBlue cells were purchased from InvivoGen and cultured according
to the manufacturer’s recommendations. The cells express TLRs 1-9 as well as
NOD1/2 and are stably transfected with an NF-κB and AP-1 inducible secreted
embryonic alkaline phosphatase (SEAP) reporter gene. Upon TLR/NLR
stimulation, THP1-XBlue cells activate the transcription factors NF-κB and AP-1,
and SEAP is secreted. SEAP can be detected by QUANTI-Blue (InvivoGen),
which turns blue/purple in the presence of SEAP. Heat killed Listeria
monocytogenes (HKLM) (InvivoGen) was used as a positive control for TLR2 and
LPS-EB (InvivoGen) was used as a positive control for TLR4. The TLR assay
was conducted according to the manufacturer’s instructions. Briefly, cells were
plated at 200,000 cells per well in a 96 well plate. Cells were treated with 0.6ug
seasonal influenza vaccine, 0.6ug H5N1 vaccine, 10ul of 1ug/ml LPS, or 10ul of
reconstituted HKLM (109 cells/mL) for 24 hours. Following the overnight
incubation, cell supernatants were incubated with QUANTI-Blue for 2 hours and
SEAP levels were determined using a spectrophotometer at 620-655 nm.
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C-Type Lectin Receptor Binding Assays
BMDCs were pre-treated with increasing concentrations of either mannan
(0ug/ml, 12.5ug/ml, 25ug/ml, 50ug/ml), mannose (0mg/ml, 0.5mg/ml, 5mg/ml,
10mg/ml, 20mg/ml), or HPAI vaccine (0ug/ml, 0.5ug/ml, 1ug/ml, 1.5ug/ml,
2ug/ml) for 30 min at 4°C. Cells pre-treated with mannan or mannose were
treated with either seasonal influenza vaccine or HPAI vaccine at 0.6ug/ml
overnight. Cells pre-treated with HPAI vaccine were treated with seasonal
vaccine at 0.6ug/ml or mannose at 50ug/ml overnight. Cytokine expression was
determined by ELISA as described previously.

Results
Antibody Titers in Vaccinated Mice
Human clinical trials have demonstrated that robust protective antibody
responses are produced in response to seasonal influenza vaccination, but
vaccination with the H5N1 vaccine leads to a much weaker antibody response
[11, 12]. To examine differences in antibody production following vaccination, six
to eight week old BALB/c mice were given either a subcutaneous (SC) or
intramuscular (IM) injection of 0.6ug seasonal influenza or HPAI vaccine.
Functional antibody titers were assessed by neutralization assay (Figure 1a) and
total vaccine specific IgG was determined by ELISA (Figure 1b). Mice that
received the seasonal vaccine by either route of vaccination had significantly
increased levels of neutralizing antibodies compared to mice that received the
HPAI vaccine, in which the amount of neutralizing antibodies was below the level
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of detection. Eighty three percent of mice that received the seasonal vaccine SC,
and 86% of mice that received the seasonal vaccine IM, had neutralizing
antibody titers above the level considered protective (>1:40). When comparing
total vaccine specific IgG, antibody titers in mice that received the seasonal
vaccine mirrored the levels of neutralizing antibodies, and were significantly
higher than in mice that received the HPAI vaccine. While neutralizing antibodies
were not detected in mice that received an IM injection of the HPAI vaccine, low
levels of total vaccine specific IgG were observed. Levels of total vaccine specific
IgG in mice vaccinated IM with the HPAI vaccine were significantly higher when
compared to mice that received a SC injection of the HPAI vaccine.

APC Activation Following Vaccine Treatment
It is well established that an effective adaptive immune response follows
an efficient innate immune response, and the innate immune response to
vaccination is initiated by recognition of foreign antigen by APCs, such as DCs.
Following interaction with antigen, DCs become activated and produce proinflammatory cytokines such as IL-6, IL-12, and TNF-α. Pro-inflammatory
cytokine secretion is crucial for the activation and differentiation of T cells and the
progression of the immune response [14, 22]. Differences in DC activation were
evaluated in vitro by assessing pro-inflammatory cytokine production following
vaccine treatment. Bone marrow derived dendritic cells (BMDCs) from BALB/c
mice were treated with either the seasonal or HPAI vaccine for 24 hours, and
cytokine production was analyzed by ELISA. BMDCs treated with the seasonal
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vaccine produced significantly higher levels of IL-6, IL-12, and TNFα compared to
BMDCs treated with the HPAI vaccine, which did not induce cytokine production
(Figure 2a-c). LPS was used as a positive control and resulted in the production
of similar, or greater, levels of IL-6, IL12, and TNFα when compared to the
seasonal vaccine.
DCs detect antigen via germline-encoded pathogen receptors known as
Pattern Recognition Receptors (PRRs), specifically Toll-like receptors (TLRs)
[22, 23]. TLRs are a class of PRRs that reside on the cell surface or in the
endosomal compartments of innate immune cells. One of the most important
consequences of TLR signaling is the transcriptional regulation of inflammatory
genes, such as IL-6, IL-12, and TNF-α [24]. Influenza viruses activate DCs by
signaling through TLRs, specifically the endosomal TLR3 and TLR7/8 [25-27]. To
determine whether the influenza vaccine also signals through TLRs, a THP-1
reporter cell line expressing TLRs1-9 and NOD1/2 was utilized. THP-1 reporter
cells were treated with either the seasonal or HPAI vaccine. Heat-killed Listeria
monocytogenes (HKLM) and LPS were used as positive controls for TLR-2 and
TLR-4 respectively. Neither vaccine treatment stimulated TLRs nor NOD1/2,
showing levels of SEAP expression similar to that of cells treated with media
alone (Figure 3). These data demonstrate that unlike influenza viruses,
inactivated subunit vaccines targeting influenza do not signal through TLRs or
NLRs.
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C-Type Lectin Receptor Signaling Following Vaccine Treatment
C-type lectin receptors (CLRs) have been implicated as a class of PRRs
important for antigen recognition, internalization, and presentation to T cells [18,
28-30]. The signaling cascades following pathogen binding to CLRs result in the
production of pro-inflammatory cytokines [15, 18, 29]. To assess whether
influenza vaccines are binding to CLRs, BMDCs were pre-treated with increasing
concentrations of mannan, a CLR agonist, followed by treatment with either the
seasonal or HPAI vaccine, and cytokine expression was assessed by ELISA. As
expected, cells treated with the seasonal vaccine in the absence of mannan
induced cytokine secretion, whereas cells treated with the HPAI vaccine in the
absence of mannan did not produce cytokines. In cells treated with the seasonal
vaccine, as the concentration of mannan increased, the production of the
cytokines IL-6, IL-12, and TNFα decreased in a dose dependent manner (Figure
4a-c). This data suggests that mannan and the seasonal vaccine are binding to,
and signaling through, the same receptors. Interestingly, in BMDCs treated with
the HPAI vaccine, as the concentration of mannan increased, the expression of
the cytokines IL-6, IL-12, and TNFα also increased but remained lower than
cytokine levels produced by cells treated with mannan alone, suggesting that the
HPAI vaccine is binding CLRs but not inducing a signaling cascade.
In order to more clearly demonstrate that the seasonal influenza vaccine is
binding C-type lectin receptors, since mannan alone induces cytokine
expression, mannose was used to block CLRs. CLRs recognize high-mannose
structures that are able to induce receptor aggregation and consequent signaling.
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The mannose monomer binds CLRs, but due to differences in valency, does not
trigger receptor aggregation [15, 18, 31]. Following pre-treatment with mannose,
BMDCs were treated with either the seasonal or HPAI vaccine. As with the
mannan pre-treatment, in cells treated with the seasonal vaccine, as the
concentration of mannose increased, the expression of the cytokines IL-6, IL-12,
and TNF-α decreased in a dose dependent manner (Figure 5a-c). Again, this
suggests that the seasonal vaccine is activating CLRs. As expected, treatment
with the HPAI vaccine did not result in cytokine production, as this was previously
demonstrated in Figure 2.
To further assess the possibility that the HPAI vaccine binds CLRs without
inducing a signaling cascade, BMDCs were pre-treated with increasing
concentrations of HPAI vaccine following treatment with either seasonal vaccine
or mannan, and cytokine expression was assessed by ELISA. In both BMDCs
treated with the seasonal vaccine or mannan, as the amount of HPAI vaccine
increased, the expression of the cytokines IL-6, IL-12, and TNFα decreased in a
dose dependent manner (Figure 6a-c). This data further implicates CLRs as the
receptors engaged by the influenza vaccines and demonstrates that the HPAI
vaccine is binding to the receptors but not initiating a signaling cascade.

Discussion
Despite utilizing similar techniques for the production of seasonal
influenza subunit vaccines, the H5N1 subunit vaccine resulted in lower
immunogenicity when tested in clinical trials [9-12]. Vaccination is one of the
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most effective methods for preventing infectious diseases, and while the general
immune response to vaccination is understood, the precise immunological
mechanisms behind how vaccines work remain to be elucidated [13]. In the
current study, we found that the 2009/2010 seasonal influenza subunit vaccine
stimulated the immune system by binding to C-type lectin receptors and initiating
signaling cascades that led to the production of pro-inflammatory cytokines, while
the H5N1 vaccine bound C-type lectin receptors but did not initiate signaling.
The current study demonstrated that mice immunized with the seasonal
vaccine produced higher levels of both neutralizing antibodies and total vaccine
specific IgG compared to mice immunized with the H5N1 vaccine (Figure 1). The
results presented herein demonstrated that 86% of mice that received an IM
vaccination of the seasonal influenza vaccine produced neutralizing antibodies at
a titer greater than 1:40. This is comparable to data from human clinical trials in
which 70% of vaccine recipients developed protective levels of neutralizing
antibodies [11]. The production of low levels of vaccine specific total IgG in mice
that received an IM immunization of the H5N1 vaccine demonstrated that vaccine
specific antibodies are being produced, but they are non-functional. The quantity
of vaccine specific total IgG produced by mice immunized with the H5N1 vaccine
is still significantly lower than in mice immunized with the seasonal influenza
vaccine. As a good cellular immune response leads to a good adaptive immune
response, this data suggests that the mechanism behind the attenuated function
of the H5N1 vaccine occurs earlier in the immune response prior to antibody
production. The ability of seasonal influenza subunit vaccines to stimulate the
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production of antibodies in mice, as demonstrated herein, is in agreement with
previously reported studies [32, 33]. These studies, as well as others conducted
in mice, also examine cellular responses following immunization and
demonstrate that our model is sufficient for investigating the immune response to
influenza vaccination [32-36].
In the current study, BMDCs treated with seasonal influenza vaccine
produced significantly higher levels of the pro-inflammatory cytokines IL-6, IL-12,
and TNF-α compared to BMDCs treated with H5N1 vaccine, which did not induce
cytokine production (Figure 2). The ability of the seasonal vaccine to induce
cytokine expression in BMDCs is not surprising as previous studies, both in vivo
and in vitro, have demonstrated that treatment with seasonal influenza subunit
vaccines results in pro-inflammatory cytokine production [37-39]. The ability of
the seasonal influenza vaccine to induce cytokine production demonstrates that
the vaccine is able to stimulate APCs and initiate an immune response.
Therefore, the absence of cytokine production by H5N1 vaccine treated BMDCs
suggests that the HPAI vaccine is inefficient at activating APCs and results in
attenuated immunogenicity.
The production of the pro-inflammatory cytokines IL-6, IL-12, and TNF-α is
the result of the activation of transcription factors such as NF-κB, AP-1, and
IRF3/7 downstream of PRR stimulation [13, 15-18, 25, 40]. Influenza viruses are
known to activate TLR3 which recognizes dsRNA and TLR7/8 which recognizes
ssRNA [25-27]. The current study demonstrated that neither the seasonal
influenza vaccine nor the H5N1 vaccine activated TLRs or NLRs (Figure 3). At

46

first this seemed surprising, but as the manufacturing process for influenza
subunit vaccines ensures that only protein and no genetic material is left in the
vaccine preparation [41, 42], it was understandable that TLRs recognizing
genetic material were not activated. Interestingly, vaccine components did not
activate other TLRs, such as TLR2 or TLR4 which recognize various proteins
found on microbes [43-45]. NOD1 and NOD2 are most associated with the
recognition of bacterial pathogens [46]; however, one study showed the
importance of NOD2 in the recognition of ssRNA and respiratory syncytial virus
(RSV) [47], while another study demonstrated that bacteria-infected mice coinfected with murine norovirus displayed an augmentation in NOD1 and NOD2
signaling and the subsequent production of pro-inflammatory cytokines [48].
Similar to TLRs, in the case of viral pathogens, NOD1/2 appears to be
recognizing viral nucleic acid which explains the absence of activation in our
model.
As neither the seasonal vaccine nor the H5N1 vaccine activated TLRs or
NLRs in the current study, CLRs were examined since the activation of these
receptors also leads to the production of pro-inflammatory cytokines (Figure 2),
and because CLRs have been identified as an important class of PRRs involved
in antigen recognition and the initiation and regulation of the immune response to
microbial infection [15, 18, 28-30]. Herein, pre-treatment of BMDCs with
increasing concentrations of mannan (Figure 4) or mannose (Figure 5) led to a
dose dependent decrease of pro-inflammatory cytokine production following
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treatment with the seasonal influenza vaccine. This data implicates CLRs as the
PRRs engaged by the seasonal influenza vaccine.
CLRs recognize pathogens via mannose, fucose, and glucan
carbohydrate structures present on microbes, with mannose being important for
the recognition of viruses [15]. CLR activation results in receptor aggregation and
subsequent signaling pathways are induced by two general mechanisms. CLRs
such as Mincle, Dectin 2, BDCA2, and CLEC5A induce signaling through
molecules that contain immunoreceptor tyrosine-based activation motifs (ITAMs)
such as FcRy or DAP12. CLRs such as Dectin 1, DC-SIGN, DCIR, and
CLEC12A induce signaling through the activation of protein kinases or
phosphatases, such as Src family kinases and the recruitment of the kinase Syk,
which interact with the cytoplasmic domains of the receptors [15, 18]. These
mechanisms can influence the design of future studies aimed to identify the
specific CLRs involved in influenza vaccine recognition.
The HA, NA, and M2 surface proteins of the influenza virus are all targets
of adaptive immunity [49], and the HA and NA proteins are the antigens present
in the vaccine preparation [41]. The HA protein contains glycosylation sites [50]
which could be recognized by CLRs. Interestingly, influenza viruses have not
been shown to signal through CLRs; however, a recent study demonstrated that
concurrent influenza infection and exposure to allergens resulted in an increase
in CLR gene expression [51]. Our findings suggest that CLRs play an important
role in immune recognition of inactivated subunit influenza vaccines.
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In the current study, pre-treatment with increasing concentrations of either
mannan or mannose resulted in a dose dependent decrease in cytokine
production following treatment with the seasonal vaccine (Figures 4 and 5),
providing a role for CLRs in vaccination against influenza. Following pretreatment with mannan, cells that were treated with H5N1 vaccine secreted
roughly the same amount of cytokines as cells treated with mannan alone (Figure
4). This data suggests that the H5N1 vaccine binds CLRs but does not initiate
signaling. To substantiate this finding, BMDCs were pre-treated with increasing
concentrations of H5N1 vaccine followed by treatment with either seasonal
vaccine or mannan, and cytokine production again decreased in a dose
dependent manner, confirming that the H5N1 vaccine is binding CLRs but not
initiating a signaling cascade (Figure 6). These results provide a mechanism for
the decreased immunogenicity of the H5N1 vaccine. The difference in the ability
of the seasonal and H5N1 vaccines to activate CLRs suggests a variation in the
glycosylation sites present on the HA proteins from the different viruses. Further
studies elucidating the specific CLRs involved in influenza vaccine recognition
will be important for advancing the knowledge behind the mechanisms of the
immune response to influenza vaccines. Furthermore, identifying potential
differences in glycosylation patterns on the HA proteins of the different viruses
would contribute to the findings presented herein.
The use of vaccines is imperative for the control of infectious diseases;
however, the mechanisms behind vaccine immunogenicity are incompletely
understood [13]. Identifying the means by which specific vaccines confer
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protection from pathogens will lead to the development of more effective
vaccines. Our findings, presented herein, elucidate a mechanism by which the
2009/2010 seasonal influenza subunit vaccine gives rise to a protective antibody
response whereas the H5N1 vaccine elicits an attenuated antibody response,
and provide insight into the development of more immunogenic vaccines
targeting HPAI.
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Figure Legends
Figure 1. Increase in vaccine specific antibody responses in BALB/c mice
vaccinated with seasonal influenza vaccine but not HPAI vaccine. Male
BALB/c mice were given either a subcutaneous (SC) or intramuscular (IM)
injection of seasonal vaccine, HPAI vaccine, or saline. Sera were collected 3
weeks later and antibody titers determined by neutralization assay or ELISA. A.
Neutralizing antibody titers in mice treated with seasonal vaccine SC (squares),
HPAI vaccine SC (triangles), seasonal vaccine IM (circles), or HPAI vaccine IM
(upside down triangles). Error bars indicate mean ± SEM (*p<.05, **p<.005,
Student’s t-test). B. Total vaccine specific IgG as determined by ELISA in mice
treated with saline IM (closed circles), saline SC (squares), seasonal SC
(triangles), HPAI SC (upside down triangles), seasonal IM (diamonds), or HPAI
IM (open circles). Error bars indicate mean ± SEM (*p<.05, **p<.001, ***p<.0001,
Student’s t-test).

Figure 2. Increased cytokine production after treatment of BMDCs with
seasonal vaccine but not HPAI vaccine. BMDCs were treated with seasonal
vaccine (checkered bars), HPAI vaccine (white bars), LPS (striped bars), or
media alone (black bars) for 24 hours. Cytokine production was determined by
ELISA. A. IL-6 production in vaccine treated BMDCs expressed as mean ± SEM
(***p<.0005, Student’s t-test). B. IL-12 production by vaccine treated BMDCs
expressed as mean ± SEM (**p<.005, Student’s t-test). C. TNF-α production in
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vaccine treated BMDCs expressed as mean ± SEM (****p<.0001, Student’s ttest). Results represent three independent experiments.

Figure 3. Neither vaccine stimulates Toll-like or NOD-like receptors. THP1XBlue reporter monocytes expressing TLRs 1-9 and NOD1/2 transfected with
SEAP were treated with seasonal vaccine (checkered bars), HPAI vaccine (white
bars), LPS (striped bars), HKLM (diagonal bars), or media alone (black bars) for
24 hours. Cell supernatants were then incubated in the presence of QUANTIBlue for 2 hours and SEAP expression was determined using a
spectrophotometer. LPS was used as a positive control for TLR4 and HKLM was
used as a positive control for TLR2. Results represent two independent
experiments.

Figure 4. Influenza vaccines bind the same receptors as mannan. BMDCs
were pre-treated with increasing concentrations of mannan followed by treatment
with either seasonal influenza vaccine or HPAI vaccine for 24 hours, and
cytokine production was assessed by ELISA. A. IL-6 production by vaccine
treated BMDCs pre-treated with increasing concentrations of mannan (p<.0001,
Two-way ANOVA comparing all groups). B. IL-12 production by vaccine treated
BMDCs pre-treated with increasing concentrations of mannan (p<.0001, Twoway ANOVA comparing all groups). C. TNF-α production by vaccine treated
BMDCs pre-treated with increasing concentrations of mannan (p<.0001, Two-
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way ANOVA comparing all groups). Results represent two or more independent
experiments.

Figure 5. The seasonal influenza vaccine signals through C-type lectin
receptors. BMDCs were pre-treated with increasing concentrations of mannose
followed by treatment with either seasonal vaccine or HPAI vaccine for 24 hours,
and cytokine production was assessed by ELISA. A. IL-6 production by vaccine
treated BMDCs pre-treated with increasing concentrations of mannose (p<.0001,
Two-way ANOVA comparing all groups). B. IL-12 production by vaccine treated
BMDCs pre-treated with increasing concentrations of mannose (p<.0001, Twoway ANOVA). C. TNF-α production by vaccine treated BMDCs pre-treated with
increasing concentrations of mannose (p<.0001, Two-way ANOVA). Results
represent two independent experiments.

Figure 6. HPAI vaccine binds C-type lectin receptors without signaling.
BMDCs were pre-treated with increasing concentrations of HPAI vaccine
followed by treatment with either seasonal vaccine or mannan for 24 hours, and
cytokine expression was assessed by ELISA. A. IL-6 production by vaccine
treated BMDCs pre-treated with increasing concentrations of HPAI vaccine
(p<.05, Two-way ANOVA comparing all groups). B. IL-12 production by vaccine
treated BMDCs pre-treated with increasing concentrations of HPAI vaccine
(p<.0005, Two-way ANOVA comparing all groups). C. TNF-α production by
vaccine treated BMDCs pre-treated with increasing concentrations of HPAI
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vaccine (p<.0005, Two-way ANOVA comparing all groups). Results were
obtained from two independent experiments.
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Abstract
Highly pathogenic avian influenza (HPAI) H5N1 is an emerging infectious
virus with an approximate 60% fatality rate in humans. In the United States, a
vaccine for H5N1 has been developed and stockpiled in case of a pandemic;
however, the vaccine demonstrated low immunogenicity in clinical trials.
Adjuvants can be used to enhance the immune response to antigens. In this
study, we examined differences in the immune response to the H5N1 vaccine
with or without the addition of an alum adjuvant in a lethal challenge mouse
model of HPAI infection. Mice treated with the adjuvanted vaccine displayed
significantly reduced weight loss, increased survival, and higher neutralizing
antibody titers compared to mice treated with the non-adjuvanted vaccine.
Dendritic cells (DCs) cultured with the adjuvanted vaccine displayed increased
expression of the activation markers CD40, CD86, and MHC II compared to DCs
treated with the non-adjuvanted vaccine. DCs treated with HPAI vaccine with or
without alum adjuvant did not produce pro-inflammatory cytokines nor signal
through the NLRP3 inflammasome. When treated with the adjuvanted vaccine,
DCs demonstrated increased vaccine uptake and phagosomal activity compared
to those treated with the non-adjuvanted vaccine. Our study demonstrates that
the alum adjuvant rescues vaccine immunogenicity and improves survival in the
host by facilitating increased antigen uptake and intracellular processing, and
provides insight into the development of more immunogenic vaccines targeting
HPAI.
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Introduction
Highly pathogenic avian influenza (HPAI) H5N1 viruses typically infect
avian species but are extremely lethal in humans. Symptoms include fast
progressing pneumonia, respiratory distress syndrome, damage to the central
nervous system, and multi-organ failure [1, 2]. These viruses have resulted in
more than 600 human infections documented in 15 countries since 2003, and
have had an approximate 60% fatality rate with death usually occurring 10 days
after symptom onset in fatal cases [1-4]. Despite the emergence of a novel H7N9
avian influenza outbreak in humans, H5N1 cases continue and little evidence
exists suggesting that H5N1 prevalence has abated. Currently, transmission
between humans is sporadic; however, enhanced transmission though viral
adaptation is plausible thus making an H5N1pandemic feasible [4-6].
In preparation for a pandemic, the United States government stockpiled 20
million doses of an inactivated subunit vaccine for HPAI; however, this vaccine
resulted in low immunogenicity in human clinical trials with only 22% of recipients
developing protective antibody titers of 1:40 or greater [7, 8]. Previous studies in
our laboratory, using a lethal challenge ferret model of HPAI infection,
demonstrated that the HPAI vaccine provided only limited protection with 0%64% survival depending on the dose administered. When an alum adjuvant was
added to the HPAI vaccine, survival improved significantly to 93%, and the
vaccine was safe and well tolerated [9].
Adjuvants are substances that can influence and enhance the immune
response to antigens [10]. Vaccines that contain purified antigen, rather than
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intact pathogens, often contain adjuvants in order to amplify the immune
response to the vaccine [11]. The most commonly used adjuvant in vaccines
worldwide is alum, a mixture of aluminum salts [10, 12, 13]. The mechanism by
which alum functions as an adjuvant remains controversial and unclear with
multiple possible mechanisms described [14-17]. One proposed theory is that
alum binds to vaccine components causing them to be slowly released to the
immune system over time [10, 11]. Some reports have shown that alum can also
work by activating the NLRP3 inflammasome immune complex, while others
have shown that this is not the primary mechanism of action for alum [14, 18].
Additionally, previous studies have demonstrated that alum increases antigen
internalization by dendritic cells (DCs) through binding to cell membrane lipids
thereby triggering an endocytic response and signaling cascades that result in
CD4+ T cell activation and humoral immune responses [15-17].
Herein, immunization in a lethal challenge mouse model was utilized to
elucidate the mechanism by which alum enhances HPAI vaccination. We show
that, in vivo, the addition of alum to the HPAI vaccine increased neutralizing
antibody titers and survival in BALB/c mice, while in vitro, treatment with the
adjuvanted vaccine resulted in up-regulation of the cell surface markers CD40,
CD86, and MHC II on DCs. Surprisingly, the addition of an alum adjuvant to the
HPAI vaccine did not induce NLRP3 inflammasome activation nor production of
pro-inflammatory cytokines. Furthermore, the addition of alum to the H5N1
vaccine increased antigen uptake and intracellular processing in DCs. Our
results indicate that the H5N1 split virion vaccine is unable to induce an early
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antigenic response in APCs, but this can be overcome by the addition of an alum
adjuvant.

Materials and Methods
Mice
Male BALB/c mice, aged six to eight weeks, were purchased from the
National Cancer Institute at Frederick (NCI-Frederick, Bethesda, MD), and held
for 21 days for quarantine and acclimation. Mice were housed four per cage in
microisolator cages under identical husbandry conditions and fed certified
commercial feed. Animals were identified by BMDS microchips (IPTT-300
Implantable Programmable Temperature and Identification Transponder from Bio
Medic Data System, Inc. (BMDS) Seaford, DE) inserted subcutaneously between
the shoulder blades, and cage cards. All animal studies were approved by the
Lovelace Respiratory Research Institute Institutional Animal Care and Use
Committee.

Vaccines
The following reagent was obtained through the National Institutes of
Health (NIH) Biodefense and Emerging Infections (BEI) Research Resources
Repository, NIAID, NIH: Monovalent Influenza Subvirion Vaccine,
rg/A/Vietnam/1203/2004, NR-4143 at a concentration of 30ug/ml hemagglutinin
protein. Adjuvanted H5N1 Monovalent Influenza subvirion vaccine,
rg/A/Vietnam/1203/2004, with a proprietary concentration of alum adjuvant was
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provided under contract from DMID/NIAID/NIH at two concentrations of
hemagglutinin (HA) protein: 45ug/ml (lot UD07828) and 15ug/ml (lot UD07826),
or was prepared by research staff at a concentration of 1200ug alum (Invitrogen,
Grand Island, NY) per 1 ml of the provided non-adjuvanted vaccine [19].
Vaccines were diluted to 0.6ug/ml HA protein with 0.05ml physiological saline
immediately prior to vaccination.

Virus
Influenza virus A/Vietnam/1203/2004 (VN1203) subtype H5N1 was
obtained from the Centers for Disease Control and Prevention (Atlanta, GA) as
low-passage stock. The virus was passaged once in 10-day old embryonated
chicken eggs to generate the master stock and then twice in eggs to generate
the virus for all subsequent uses. Aliquots of 0.5ml to 1ml were stored at -80°C.
After storage, the virus was determined to have a concentration of 1.4 x 108
plaque forming units (pfu/ml), 5.8 x 108 50% tissue culture dose (TCID50/ml), and
1 x 108 50% egg infectious dose (EID50/ml). Influenza A/Vietnam/1203/2004 is a
Risk Group 3 pathogen and all experiments involving this virus were carried out
in a Biosafety Level 3 (BSL 3) containment facility at the Lovelace Respiratory
Research Institute and approved by the Institutional Biosafety Committee.

Immunization and Viral Challenge
Mice (n = 6 per group) were given a primary or a primary and secondary
intramuscular injection in the gastrocnemius muscle of the H5N1 vaccine with or
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without alum adjuvant. Secondary vaccinations were administered three weeks
following primary vaccinations. Control animals received intramuscular injections
of 0.05ml physiological saline. Seven weeks following primary vaccination, mice
were challenged intranasally (IN) with a lethal dose (10 pfu) of
A/Vietnam/1203/2004 (VN1203), and morbidity and mortality were assessed.
Twice daily observations were conducted to determine animal health by
appearance and activity. The injection site was monitored for inflammation and
irritation. Body temperatures and bodyweights were recorded before vaccination,
weekly prior to challenge, and daily thereafter. Animals were considered
moribund if they experienced greater than 15% weight loss.

Serology
Blood for serum was collected from mice at necropsy by cardiac puncture
three weeks after primary vaccination or four weeks after secondary vaccination.
Blood was placed in serum separator collection tubes and incubated at room
temperature for 30 minutes before centrifugation at 2500rpm for 10 min. Serum
was collected and stored at -20°C until analyzed. The neutralization assay was
modified from previously described procedures [20]. Briefly, serum samples were
treated with receptor-destroying enzyme (Enka-Seiken, Tokyo, Japan) at a ratio
of 1:1 followed by heat inactivation at 56°C for 45 minutes. The serum samples
were incubated with 2 x 103 TCID50 A/Vietnam/1203/2004 at 37°C for one hour.
After incubation, Madin-Darby Canine Kidney (MDCK) cells plated in 96 well
plates were inoculated in triplicate with the samples using a 2-fold dilution and
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incubated at 37°C for three days. The plates were then scored for cytopathic
effect (CPE), and neutralizing antibody titers were determined as the highest
serum dilution at which no CPE occurred [9, 21].

Primary Bone Marrow Cell Isolation, Culture, and Treatment
Bone marrow cells were collected and cultured as previously described
[22]. Briefly, bone marrow cells were isolated from the femurs and tibiae of mice
and cultured in complete RPMI media (Invitrogen, Carlsbad, CA) containing 10%
FBS (Invitrogen), 1x penicillin/streptomycin (Invitrogen), and 25ng/ml GM-CSF
(Cell Signal Technology, Danvers, MA) for 5-7 days at 37°C with 5% CO2. The
following treatments were given in complete RPMI for 2 or 24 hours for in vitro
experiments: 0.6ug/ml (HA protein) of non-adjuvanted HPAI vaccine; 0.6ug/ml
(HA protein) of adjuvanted HPAI vaccine; 250ug/ml alum (Invivogen, San Diego,
CA).

Treatment with Acridine Orange
Evaluation of phagosomal activity was assessed using modifications to
previously described procedures [23]. BMDCs cultured as described above were
pre-treated with 0.5ug/ml acridine orange (Invitrogen) for 15 min at 37°C prior to
above treatments for select experiments and analyzed by flow cytometry.
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Treatment with FITC Conjugated HPAI Vaccine
The adjuvanted and non-adjuvanted HPAI vaccines were conjugated to
FITC (Thermo Scientific, Waltham, MA) using modifications to previously
described procedures and the manufacturer’s instructions [24]. Briefly, 15- to 20fold molar excess of FITC was added to one vial of vaccine and incubated at
room temperature for one hour in the dark. Excess and hydrolyzed FITC was
removed by dye column removal kits (Thermo Scientific). BMDCs cultured as
described above were treated with the FITC conjugated vaccine for 2 hours and
analyzed by flow cytometry. For microscopy experiments, Armenian hamster
anti-mouse CD11c clone N418 conjugated to PE-Cy7 (eBioscience, San Diego,
CA) was used as a cell surface marker.

Flow Cytometry
In vitro experiments for cell surface marker expression, as well as those
using acridine orange pre-treated cells, and cells treated with the FITC
conjugated vaccines were analyzed by flow cytometry. Antibodies utilized
include: Armenian hamster anti-mouse/rat CD40 clone HM40-3 conjugated to
FITC (eBioscience); rat anti-mouse CD86 clone GL1 conjugated to PE
(eBioscience); and rat anti-mouse MHC II I-A/I-E clone M5/114.15.2 conjugated
to PerCP/Cy5.5 (BioLegend, San Diego, CA). Samples were run on a FACS
Canto flow cytometer (BD Bioscience, San Jose, CA) and analyzed by FlowJo
cytometry analysis software (TreeStar, Ashland, OR). Cell populations were
gated on viable cells and assessed for expression in the FL1 (CD40 and FITC),
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FL2 (CD86), or FL3 (MHC II and acridine orange) channels. Compensation was
calculated using BD CompBeads (BD Bioscience). For each experiment, treated
cells were compared to cells in culture media alone.

ELISA
BMDC culture supernatants were analyzed for IL-6, IL-12, IL-1β, and TNFα production using ELISA kits purchased from eBioscience according to the
manufacturer’s instructions.

Widefield Fluorescence Microscopy
Images were acquired on an Olympus IX81 microscope using an LCAch N
40x/0.55 air UIS2m objective. Acridine orange was imaged using a 452 dichroic
and a 520-550 emission filter. FITC was imaged using a 495 dichroic and a
502.5-537.5 emission filter. CD11c-PE-Cy7 was imaged using a 760 dichroic and
a 765-855 emission filter. Acquisition was done using Metamorph (Molecular
Devices, Sunnyvale, CA), and image processing done using ImageJ (National
Institutes of Health, Bethesda, MD.).

Statistical Analysis
Bodyweights, body temperatures, and neutralizing antibody titers are
expressed as mean values from each group of n = 6 mice. All statistical analysis
was completed using the analysis software included in GraphPad Prism
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(GraphPad Prism 5 for Windows, version 5.03; GraphPad Software, Inc., La
Jolla, CA.).

Results
Morbidity and Mortality Following HPAI Challenge in Vaccinated Mice
Previous studies have shown that the subunit vaccine targeting H5N1 is
not protective in a lethal challenge ferret model unless supplemented with an
alum adjuvant [9]. As limited immunologic reagents are available for exploring
molecular mechanisms in ferrets, we examined the immune response to H5N1
vaccination in a lethal challenge BALB/c mouse model of H5N1 infection. To
assess protection conferred by the HPAI vaccine, BALB/c mice (n=6 per group)
were given a primary intramuscular (IM) vaccination of the HPAI vaccine (0.6ug)
with or without an alum adjuvant, and challenged intranasally (IN) with a lethal
dose (10 pfu) of A/Vietnam/1203/2004 (VN1203) 7 weeks following vaccination.
Non-vaccinated challenged control mice began losing weight 3 days post
infection (dpi) (Figure 1a), and mortality began 5 dpi with 100% mortality
occurring by 7 dpi (Figure 1b). Mice that received the non-adjuvanted vaccine
began losing weight 4 dpi and weight loss peaked 7 dpi before recovering in
surviving animals. Mortality in mice that received the non-adjuvanted vaccine
began 6 dpi with 33% of animals surviving. Mice that received the adjuvanted
vaccine had similar weight loss initially to those that received the non-adjuvanted
vaccine beginning 4 dpi; however, weight loss did not progress in this group
beyond 5 dpi. Animals that received the adjuvanted vaccine achieved 83%
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survival with one death 8 dpi. Non-vaccinated, non-challenged control animals
exhibited steady bodyweights and had 100% survival as expected. Taken
together, these results demonstrate that the addition of an alum adjuvant to the
HPAI vaccine provides greater protection in BALB/c mice, and these results are
similar to those observed previously in a ferret model [9].

Neutralizing Antibody Titers in Vaccinated Mice
To evaluate differences in the production of functional antibody titers to
HPAI in vaccine treated animals, BALB/c mice (n=6 per treatment) received a
primary or a primary and secondary IM vaccination of 0.6ug of the HPAI vaccine
with or without the addition of an alum adjuvant. Antibody titers were assessed
by neutralization assay 21 days following primary vaccination and 28 days
following secondary vaccination. Neutralizing antibody titers were observed in
50% of mice that received a primary vaccination of the adjuvanted HPAI vaccine,
but were below the level considered protective (>1:40). Neutralizing antibodies
were not detected in mice that received a primary vaccination of the nonadjuvanted HPAI vaccine (Figure 2a). All mice that received a primary and
secondary vaccination of either the adjuvanted or non-adjuvanted HPAI vaccine
developed neutralizing antibody titers. Of the mice that received the adjuvanted
vaccine, 83% developed antibody titers greater than 1:40, whereas only 33% of
mice that received the non-adjuvanted vaccine developed antibody titers greater
than 1:40. Neutralizing antibody titers in mice that received the adjuvanted
vaccine were significantly higher compared to mice that received the non-
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adjuvanted vaccine (Figure 2b). These results illustrate that the addition of an
alum adjuvant increased neutralizing antibody titers against VN1203 in BALB/c
mice.

Dendritic Cell Activation Following Vaccine Treatment
It is recognized that an effective innate immune response contributes to a
functional adaptive immune response, and dendritic cells (DCs) are well
established as antigen presenting cells. The ability of DCs to process antigen
and drive T cell responses makes them an important cell type in vaccination, and
many vaccines are being developed to specifically target DCs [25-27]. Upon
activation, DCs up-regulate the expression of cell surface markers such as
CD40, CD80/86, and MHC II [28]. We examined differences in DC activation
following treatment with the HPAI vaccine with or without alum adjuvant in vitro.
Bone marrow derived dendritic cells (BMDCs) were treated with either the
adjuvanted or non-adjuvanted HPAI vaccines, and stained for the cell surface
activation markers CD40, CD86, and MHC II. BMDCs treated with adjuvanted
HPAI vaccine showed increased expression of CD40, with approximately 60%
positive (Figure 3a and d), CD86 (55% positive) (Figure 3b and e), and MHC II
(80% positive) (Figure 3c and f) compared to BMDCs treated with the nonadjuvanted HPAI vaccine and relative to non-treated cells in media alone. Cell
surface marker expression on BMDCs treated with the non-adjuvanted HPAI
vaccine was similar to expression on non-treated cells, and treatment with alum
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alone did not result in the up-regulation of cell surface marker expression (data
not shown).
Antigen recognition by DCs can also result in intracellular signaling
cascades that lead to the secretion of pro-inflammatory cytokines such as IL-6,
IL-12, TNF-α, and IL-1β [29-31]. Alum has been previously shown to stimulate
the NLRP3 inflammasome pathway resulting in pro-inflammatory and antimicrobial responses. Inflammasome activation is characterized by the secretion
of the pro-inflammatory cytokines IL-1β and IL-18 [14, 32]. To assess whether
alum is inducing inflammasome involvement in response to H5N1 vaccination,
murine bone marrow derived dendritic cells (BMDCs) were treated with either the
adjuvanted or non-adjuvanted HPAI vaccine and cell culture supernatants were
collected and assessed for the expression of the cytokine IL-1β by ELISA. LPS +
ATP was used as a positive control and produced a robust IL-1β response. When
treated with either the adjuvanted or non-adjuvanted HPAI vaccines, BMDCs did
not secrete IL-1β (Figure 4a). These results suggest that the mechanism of
action of alum in this system is not NLRP3 inflammasome pathway activation.
To further assess whether vaccine stimulation resulted in pro-inflammatory
responses, cell culture supernatants from vaccine-treated BMDCs were analyzed
for the production of the cytokines IL-6, IL-12, and TNF-α by ELISA. LPS was
used as a positive control and resulted in the secretion of high levels of all three
pro-inflammatory cytokines. Surprisingly, the HPAI vaccine with or without the
addition of an alum adjuvant failed to induce the production of these cytokines
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(Figure 4b-d). These results demonstrate that neither vaccine stimulated
signaling pathways that lead to pro-inflammatory cytokine secretion.

Vaccine Uptake and Intracellular Processing
A recent study has shown that alum can function as an adjuvant by
directly promoting antigen uptake by DCs [15]. To determine if alum is
functioning in this manner in this model, we next examined the ability of BMDCs
to take up the HPAI vaccine with or without alum adjuvant. Briefly, BMDCs were
treated with FITC-conjugated, adjuvanted or non-adjuvanted vaccine for two
hours. FITC expression was measured and quantified using flow cytometry
(Figure 5a and b). BMDCs treated with the adjuvanted vaccine demonstrated a
clear increase in FITC expression compared to BMDCs treated with the nonadjuvanted vaccine (Figure 5a). Fluorescence intensity was quantified and
increased by 10-fold in cells treated with the adjuvanted vaccine compared to
cells treated with the non-adjuvanted vaccine (Figure 5b). Vaccine uptake was
further assessed by fluorescent microscopy, and BMDCs treated with the FITCconjugated, adjuvanted HPAI vaccine revealed more intense fluorescence
compared to cells treated with the non-adjuvanted vaccine (Figure 5c).
To assess differences in antigen processing following vaccine uptake, we
examined phagosomal activity post vaccine treatment using acridine orange
quenching. The dye acridine orange has been used previously to examine
activity within acidic cellular compartments [23, 33, 34]. Acridine orange becomes
highly concentrated in acidic cellular compartments and is sensitive to changes in
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pH; therefore, fluorescence quenching can be used to quantify phagosomal
activity [23]. BMDCs were pre-treated with acridine orange followed by treatment
with the HPAI vaccine with or without adjuvant for 2 hours. Cells were collected
and analyzed by fluorescence microscopy and flow cytometry, and phagosomal
activity was observed as a decrease in acridine orange expression. Cells treated
with alum, acridine orange alone, or non-adjuvanted HPAI vaccine expressed
high levels of acridine orange, suggesting little activity in phagosomal processing.
Cells treated with adjuvanted HPAI vaccine had decreased acridine orange
fluorescence compared to the other treatments, indicating an increase in
phagosomal activity (Figure 6a-c). Taken together, these results illustrate that the
addition of an alum adjuvant to the HPAI vaccine results in increased vaccine
uptake by BMDCs, which in turn, results in increased intracellular processing,
when compared to BMDCs treated with the non-adjuvanted HPAI vaccine.

Discussion
An inactivated subunit vaccine targeting H5N1 resulted in low
immunogenicity when evaluated in human clinical trials [7]; however, studies
conducted in a lethal challenge ferret model demonstrated that the addition of an
alum adjuvant to the H5N1 vaccine resulted in increased survival and functional
antibody production [9]. The mechanism of action of alum as an adjuvant is
multifaceted and controversial [14-17]. In the current study, we found that alum
enhances the immune response to the H5N1 vaccine by facilitating increased
antigen uptake and intracellular processing. The addition of alum to the HPAI
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vaccine resulted in decreased morbidity and mortality in a lethal challenge mouse
model (Figure 1), as well as the increased production of neutralizing antibodies in
vaccinated animals (Figure 2). These results coincide with previous findings in
ferrets, and show that our model is sufficient for studying the immune response
to HPAI vaccination [9]. The ferret model is less suited to study the immune
response as limited immunological reagents are available.
In the current study, BMDCs treated with the alum-adjuvanted HPAI
vaccine had increased expression of the co-stimulatory markers CD40, CD86,
and MHC II compared to cells treated with the non-adjuvanted HPAI vaccine
(Figure 3), which demonstrates that the addition of alum to the vaccine
preparation led to the activation of APCs. These results were expected as
previous studies have shown the ability of alum, when in the presence of antigen,
to upregulate CD40, CD86, and MHC II on monocytes and macrophages [35-38].
The activation of APCs and the subsequent upregulation of co-stimulatory
molecules on the cell surface are critical for the presentation of antigen to T cells
and the progression of a productive immune response [28, 35].
While our data demonstrated that the addition of alum to the HPAI vaccine
was able to activate DCs, neither treatment with adjuvanted nor non-adjuvanted
vaccine resulted in the production of the pro-inflammatory cytokines IL-6, IL-12,
or TNF-α (Figure 4b-d). While previous studies have shown that alum alone does
not induce expression of these cytokines, as they are associated with T H1
responses and not TH2 responses [11, 14], it is interesting that other vaccine
components did not initiate cytokine production. An in vivo study of influenza
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vaccination in mice demonstrated that vaccination with a seasonal influenza
subunit vaccine resulted in the production of the cytokines IL-6 and TNF-α in the
lungs [39]. In vitro, a study in mice showed that following treatment with a subunit
seasonal influenza vaccine, DCs produced low levels of IL-6 and TNF-α, but no
detectable IL-12 [40], while another study detected low levels of TNF-α but no
detectable IL-12 from DCs isolated from human PBMCs and treated with a
subunit seasonal influenza vaccine [41]. Together, these studies demonstrate
that cytokine production by APCs following vaccination with subunit seasonal
influenza vaccines in vivo can be expected, while, in vitro, production of the
cytokines IL-6 and TNF-α by vaccine treated DCs is less pronounced but still
detectable. This suggests that the HPAI vaccine used in our study is less efficient
than the seasonal influenza subunit vaccines in activating DCs.
In addition to IL-6, IL-12, and TNF-α, BMDCs treated with the alumadjuvanted HPAI vaccine did not produce IL-1β (Figure 4a). This was surprising
as alum has been previously shown to signal through the NLRP3 inflammasome
complex, and the production of IL-1β is a result of activating this immune
complex [14, 32]. The lack of inflammasome involvement in our study could be
explained by the fact that inflammasome activation and the subsequent
production of IL-1β require two signals. Alum is known to provide the second
signal, which directly activates Nlrp3. The first signal is provided by endogenous
or microbial antigens that activate NF-κB [14, 32]. It appears that, in our study,
following treatment with the alum-adjuvanted HPAI vaccine, the first signal is
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missing. This idea is supported by the lack of production of IL-6, IL-12, and TNFα, which are downstream of NF-κB activation [42].
Herein, alum was able to facilitate increased antigen uptake in vaccine
treated BMDCs (Figure 5). This finding is supported by a previous study that
demonstrated an inflammasome independent mechanism of action for alum, in
which alum acts as an adjuvant by binding to the plasma membrane of DCs and
activating endocytic uptake via delayed ERK phosphorylation leading to antigen
uptake [15]. The authors demonstrated that alum interacts with membrane lipids
on the surface of DCs, which results in the aggregation of ITAM-containing
receptors and subsequent Syk and PI3K signaling, and further demonstrated that
while allowing antigen uptake by DCs, alum itself did not enter the cell. The
findings from the current study suggest that this is the mechanism of action
employed by alum with regard to increased H5N1 vaccine immunogenicity.
Following increased antigen uptake by vaccine treated BMDCs, an
increase in antigen processing was demonstrated using acridine orange staining
in BMDCs treated with the adjuvanted vaccine compared to those treated with
the non-adjuvanted vaccine (Figure 6). This finding is consistent with the idea
that if an increased amount of antigen is internalized by the cell that an increased
amount of antigen processing will occur. This increase in antigen processing
coincides with the upregulation of MHC II on the cell surface of BMDCs treated
with the adjuvanted vaccine compared to those treated with the non-adjuvanted
vaccine (Figure 3).
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Taken together, our data suggests that the H5N1 vaccine examined in this
study is unable to efficiently stimulate DCs without the addition of an adjuvant.
The addition of alum to the vaccine preparation allows increased antigen uptake,
possibly through an endocytic response, and subsequently, increased antigen
processing. Further studies conducted in vivo of the immune mechanisms
demonstrated by the current study would contribute to the findings presented
herein. Vaccination is one of the most effective methods for preventing infectious
diseases, and while the general immune response to vaccination is understood,
the precise mechanisms behind the ability of vaccines to stimulate the immune
system and lead to long term protection remain to be elucidated [30]. Identifying
the mechanisms by which vaccines confer protection from disease will allow
more effective vaccines to be developed. This is particularly important for
pathogens for which current vaccines are not available or not sufficient, as is the
case with highly pathogenic avian influenza. Our findings, presented herein,
elucidate a mechanism by which the H5N1 vaccine offers only limited protection,
and provide insight into the development of more immunogenic vaccines
targeting HPAI.
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Figure Legends
Figure 1. Morbidity and mortality was decreased in BALB/c mice following
vaccination with adjuvanted HPAI vaccine. BALB/c mice (n=6 per group) were
vaccinated intramuscularly with adjuvanted HPAI vaccine, non-adjuvanted HPAI
vaccine, or saline. Mice were challenged intranasally 7 weeks later with 10pfu
A/Vietnam/1203/2004. A. Percent bodyweight change in surviving mice treated
with the adjuvanted HPAI vaccine (triangles), non-adjuvanted HPAI vaccine
(squares), or saline (diamonds). Non-challenged controls are represented by
circles. Percent bodyweight change is expressed as mean ± SEM (p<.0001, oneway repeated measures ANOVA comparing all groups). B. Kaplan-Meier survival
curve for mice treated with adjuvanted HPAI vaccine (dotted line), nonadjuvanted HPAI vaccine (solid line), or saline (short dashed line). Nonchallenged controls are represented by the long dashed line (p<.05, GehanBreslow Wilcoxon test comparing all groups).

Figure 2. Neutralizing antibody titers were increased in BALB/c mice
following vaccination with adjuvanted HPAI vaccine. BALB/c mice (n=6 per
group) were given a primary, or a primary and secondary, intramuscular injection
of the HPAI vaccine with or without alum adjuvant. Sera were collected 7 weeks
following primary vaccination and evaluated by neutralization assay. A.
Neutralizing antibody titers in mice following a primary vaccination of adjuvanted
HPAI vaccine (squares) or non-adjuvanted HPAI vaccine (circles). Error bars
indicated mean ± SEM (*p<.05, Student’s t-test). B. Neutralizing antibody titers in
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mice following a primary and secondary vaccination with adjuvanted HPAI
vaccine (circles) or non-adjuvanted HPAI vaccine (squares). Error bars indicated
mean ± SEM (*p<.05, Student’s t-test).

Figure 3. Expression of co-stimulatory molecules was increased on BMDCs
treated with adjuvanted HPAI vaccine. BMDCs were treated overnight at 37°C
with media alone, adjuvanted HPAI vaccine, or non-adjuvanted HPAI vaccine.
Following incubation, cells were collected and stained for co-stimulatory markers
and analyzed by flow cytometry. A-C. Expression of CD40 (A), CD86 (B), and
MHC II (C) on BMDCs treated with adjuvanted HPAI vaccine (dotted line), nonadjuvanted HPAI vaccine (solid line), or media alone (shaded area) depicted by
histograms showing fluorescence intensity. Similar results were obtained from
three independent experiments. D-F. Bar graphs illustrating percent positive of
BMDCs treated with adjuvanted vaccine (checkered bars), non-adjuvanted
vaccine (white bars), or media alone (black bars) expressing CD40 (D), CD86
(E), and MHC II (F). Error bars represent mean ±SEM (*p<.05, **p<.005,
Student’s t-test). Results were obtained from three independent experiments.

Figure 4. Neither vaccine induced cytokine production by BMDCs. BMDCs
were treated overnight at 37°C with media alone, adjuvanted HPAI vaccine, nonadjuvanted HPAI vaccine, LPS, or LPS + ATP. Cytokine expression was
assessed by ELISA. A. IL-1β secretion by BMDCs treated with media alone
(black bars), LPS + ATP (diagonal bars), adjuvanted HPAI vaccine (checkered
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bars), or non-adjuvanted vaccine (white bars). Error bars represent mean ± SEM.
B-D. Production of IL-6 (B), IL-12 (C), and TNF-α by BMDCs treated with media
alone (black bars), LPS (striped bars), adjuvanted HPAI vaccine (checkered
bars), or non-adjuvanted HPAI vaccine (white bars). Error bars represent mean ±
SEM. Results represent three independent experiments.

Figure 5. BMDCs treated with adjuvanted HPAI vaccine demonstrated
increased antigen uptake. BMDCs were treated with FITC conjugated
adjuvanted or non-adjuvanted HPAI vaccine for 2 hours at 37°C and then
analyzed for FITC expression. A. Histogram depicting fluorescence intensity of
BMDCs treated with adjuvanted HPAI vaccine conjugated to FITC (solid line) or
non-adjuvanted HPAI vaccine conjugated to FITC (dotted line) analyzed by flow
cytometry. Shaded area represents a non-stained control. B. Median
fluorescence intensity (MFI), expressed as the mean ± SEM (log10), in BMDCs
treated with adjuvanted HPAI vaccine conjugated to FITC (checkered bar) or
non-adjuvanted HPAI vaccine conjugated to FITC (white bar) as determined by
flow cytometry. The black bar represents a non-stained control (*p<.05, Student’s
t-test). Results were obtained from three independent experiments. C.
Fluorescence microscopy of BMDCs treated with either the adjuvanted or nonadjuvanted HPAI vaccines conjugated to FITC. CD11c conjugated to PE-Cy7
was used as a cell surface marker.
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Figure 6. Intracellular processing is increased in BMDCs treated with
adjuvanted HPAI vaccine. BMDCs were pre-treated with acridine orange for
15min at 37°C followed by treatment overnight with adjuvanted or nonadjuvanted HPAI vaccine. A. Histogram depicting fluorescence intensity of
BMDCs pre-treated with acridine orange followed by treatment with adjuvanted
HPAI vaccine (solid black line), non-adjuvanted HPAI vaccine (dotted line), alum
(solid grey line), or acridine orange alone (dashed line) analyzed by flow
cytometry. The shaded area represents a non-stained control. B. Median
acridine orange fluorescence (MFI), expressed as the mean ± SEM (log10) in
BMDCs treated with media alone (black bars), acridine orange alone
(crisscrossed bar), alum (dotted bar), adjuvanted HPAI vaccine (checkered bar),
or non-adjuvanted HPAI vaccine (white bar) (*p<.05, Student’s t-test). Results
were obtained from 3 independent experiments. C. Fluorescence microscopy of
BMDCs pre-treated with acridine orange followed by treatment with either the
adjuvanted or non-adjuvanted HPAI vaccine.
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CHAPTER FOUR: DISCUSSION
Summary of Studies
The purpose of these studies was to further our understanding of the
immunological mechanisms of vaccination, specifically with regard to inactivated
split virion subunit vaccines targeting influenza viruses. More precisely, the aims
of these studies were to identify mechanisms by which the seasonal and
adjuvanted H5N1 vaccines elicited a protective immune response, whereas the
non-adjuvanted H5N1 vaccine produced attenuated immunogenicity. Specifically,
these studies investigated the ability of the vaccines to activate APCs, induce the
production of neutralizing antibodies, and provide protection following lethal
challenge in a BALB/c mouse model. A more complete understanding of the
mechanisms of vaccination will lead to the development of more effective
vaccines, and the studies presented herein provide insight into the improvement
of vaccines targeting HPAI.
The immune response to subunit vaccines targeting seasonal influenza
and HPAI were examined utilizing both in vivo and in vitro experimental
approaches (Chapter 2). The seasonal and H5N1 vaccines were developed
using the same manufacturing process, but have shown disparate efficacies in
clinical trials. Regardless of the route of administration (SC or IM), the seasonal
vaccine demonstrated immunogenicity, whereas H5N1 vaccination did not result
in the production of detectable levels of neutralizing antibodies (Chapter 2, Figure
1). These findings validate the mouse model established herein as a suitable
model for studying the immune response to influenza vaccination as vaccine
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efficacy in the mouse model was comparable to that seen in humans. Studies
conducted in vitro evaluated APC activation, and demonstrated an increase in
the ability of the seasonal vaccine to activate DCs when compared to the H5N1
vaccine (Chapter 2, Figure 2). Neither vaccine stimulated TLRs or NLRs
(Chapter 2, Figure 3), and this finding led to the investigation of the involvement
of CLRs. For the first time, to our knowledge, this study demonstrates a role for
CLRs in the immune response to vaccination against influenza (Chapter 2,
Figures 4 and 5), and the ability of the H5N1 vaccine to bind CLRs but not initiate
a signaling cascade provides an explanation for the attenuated response to
H5N1 vaccination (Chapter 2, Figure 6).
In Chapter 3, the role of alum in the immune response to the H5N1
influenza subunit vaccine was evaluated in a lethal challenge mouse model of
infection. When compared to the non-adjuvanted H5N1 vaccine, treatment with
the vaccine plus alum resulted in increased immunogenicity (Chapter 3, Figure 2)
and decreased morbidity and mortality (Chapter 3, Figure 1). In vitro, the
adjuvanted H5N1 vaccine more efficiently activated APCs (Chapter 3, Figure 3);
however, neither vaccine induced the production of pro-inflammatory cytokines.
The absence of cytokine secretion suggests that neither the activation of PRRs,
nor the NLRP3 inflammasome, is involved in the mechanism of action of alum in
our model (Chapter 3, Figure 4). Herein, alum functions as an adjuvant by
facilitating increased antigen uptake and intracellular processing (Chapter 3,
Figures 5 and 6), and while alum rescues the efficacy of the H5N1 vaccine, it
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does so through a different mechanism of action than that utilized by seasonal
influenza vaccines.

Limitations of the Studies
Animal models are essential for the study of infectious diseases, as it can
be difficult and unethical to study these diseases in humans. Mice are a favorable
model in which to study immunology due to low cost, the broad availability of
immunological reagents, and transgenic strains [1, 2]. In addition, laboratory mice
are inbred and genetically identical, which facilitates reproducibility of
experimental results [3]. Despite these benefits, pathogens such as influenza do
not naturally infect mice, and thus limit their relevance [1, 2], and the inbred
nature of laboratory mice does not reflect the genetic diversity and variability
present in the human population [3]. Additionally, while studies conducted in
animal models provide invaluable insight into human biological processes,
differences in the correlates of protection between animals and humans may lead
to results obtained in an animal model that are not a true representation of the
human immune response [4, 5].
Another limitation of the current studies is that while vaccine
immunogenicity was assessed in vivo, APC activation and the mechanisms
leading to this activation were evaluated in vitro. As APC:T cell interactions can
be influenced by the lymph node micro-environment, the addition of in vivo
experiments evaluating APC activation and migration, antigen presentation to T
cells, and T cell activation would validate the findings presented herein.
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Additionally, data demonstrating APC:T cell interactions in vitro are not
included in the current studies. Experiments were conducted to assess antigen
presentation by BMDCs to T cells in vitro, yet these experiments were
unsuccessful. Ideally, T cells from transgenic mice specific for the VN1203 HA
protein would be utilized; however, such mice are not available. In an attempt to
overcome this limitation, T cells were harvested from the spleens of mice
vaccinated with either the seasonal or non-adjuvanted HPAI vaccines three
weeks following vaccination. BMDCs pulsed with the seasonal or non-adjuvanted
HPAI vaccine for 24 hours were co-cultured with T cells harvested from the
vaccinated mice for three days. T cell activation was assessed by cell
proliferation assays, but no T cell proliferation was detected.
An additional limitation of the studies presented herein is that the seasonal
influenza vaccine evaluated in the current studies is trivalent whereas the H5N1
vaccine is monovalent. The trivalent nature of the seasonal vaccine may affect its
immunogenic properties; therefore, examination of the immune response to an
efficacious monovalent subunit influenza vaccine, such as the 2009 H1N1
pandemic vaccine, would expand upon and strengthen the current studies.

Future Directions
The findings presented herein provide insight into a possible mechanism
for the attenuated function of the H5N1 vaccine. As mentioned in the limitations
section above, in vivo studies examining APC activation and migration, antigen
presentation to T cells, and subsequent T cell activation would expand on the
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current results. Draining lymph nodes should be harvested following vaccination
and assessed for cell populations and the frequencies of those populations.
Types and numbers of APCs should be identified and assessed for the
expression of co-stimulatory molecules such as CD40, CD80, and CD86, as well
as MHC I/II. The use of fluorescently labeled vaccines may help to identify APCs
that respond to antigen at the site of vaccination and then travel to the draining
lymph nodes; however, an increase in the presence of APCs alone in the
draining lymph nodes should indicate a response specific to vaccination. The
frequency of CD4+ and CD8+ T cells should also be assessed as their numbers
should be significantly higher in the lymph nodes of mice responding to
vaccination due to T cell activation and clonal expansion. Assessment of a
vaccine specific T cell response could be measured with the development and
use of fluorescent tetramers that target the HA or NA proteins from the specific
viruses used in the vaccines.
The current studies propose a role for C-type lectin receptors in the
immune response to influenza vaccination. Future studies would expand on the
involvement of CLR signaling and aim to identify the specific CLRs involved in
influenza vaccine recognition. Assays determining total phosphorylation should
be utilized as an indication for a general increase in signaling; however, these
assays would not be specific to signaling downstream of CLRs, therefore the
phosphorylation of specific CLR pathway components should be assessed. For
example, ligand binding to the CLRs Dectin-1, Dectin-2, and Mincle induces
receptor aggregation and initiates signaling through the immunoreceptor
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tyrosine-based activation motif (ITAM) on the receptors or FcRγ. Tyrosine
residues on the ITAMs are phosphorylated by Src family kinases and lead to the
recruitment and activation of the kinase Syk [6]; therefore, the expression of
phosphorylated Syk could be analyzed using western blot, or an inhibitor of Syk,
such as piceatannol could be employed. Downstream of Syk is a protein complex
consisting of CARD9, BCL10, and MALT1 (CBM), so activation of this CBM
complex could also be assessed by western blot or the utilization of BCL10
knockout mice [6, 7]. Raf-1 is another signaling component downstream of
Dectin-1, and its activation could also be assessed [6].
In addition to the analysis of the activation of signaling components
downstream of CLRs, the involvement of specific CLRs should be assessed. This
could be accomplished by using antibodies against specific CLRs that would
neutralize the receptors, blocking cellular activation. The utilization of short
hairpin RNAs (shRNAs) that silence CLR genes through RNA interference
(RNAi) could also be used to determine the involvement of specific CLRs [8, 9].
While the current studies aimed to identify variations in the immune
response to the seasonal and H5N1 vaccines, variations in the immune response
ultimately result from differences in the target viruses. The ability of the seasonal
influenza vaccine to activate C-type lectin receptors suggests that carbohydrate
structures on the HA and NA antigens are essential for vaccine antigen
recognition by these receptors. Differences in N-linked glycosylation sites on the
target viruses may account for the ability of the seasonal vaccine to activate
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signaling cascades whereas the H5N1 vaccine bound the receptors but did not
initiate signaling.
Glycosylation sites are determined by the amino acid sequence motif N-XT/S where X is any amino acid except proline [10, 11]. Previous studies have
determined the glycosylation sites on the viruses used in the vaccines studied
herein. The HA protein of A/Brisbane/10/2007, the H3N2 virus used in the
2009/2010 seasonal influenza vaccine, has potential glycosylation sites at amino
acid residues 63, 122, 126, 133, 144, and 165 [11]. The possible glycosylated
residues on the HA protein of A/Brisbane/59/2007, the H1N1 virus used in the
2009/2010 seasonal influenza vaccine, are at amino acid residues 15, 27, 58, 91,
129, 163, and 290 [12]. The HA protein of A/Vietnam/1203/2004 (VN1203), the
virus used in the H5N1 vaccine, has potential glycosylated positions at residues
22, 34, 158, 165, 176, 204, 297, 495, and 555 [10, 13]. The glycosylation site at
158 on VN1203 has been previously shown to decrease the antigenicity and
immunogenicity of a live attenuated H5N1 vaccine studied in ferrets [13]. Future
studies should aim to identify whether the addition or removal of glycosylation
affects the ability of the influenza vaccines to bind and activate CLRs, and would
determine the viral motifs recognized by the receptors. Motif recognition could
also be examined utilizing viral peptide arrays and assessing CLR activation
following treatment with peptides.
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Conclusions
Highly pathogenic avian influenza is an emerging infectious virus with the
potential to cause a pandemic, and cases of both H5N1 and H7N9 are currently
circulating in humans. The first study described in this dissertation compared the
immune response to inactivated subunit vaccines targeting seasonal and H5N1
influenza viruses, as well as, defined a mechanism for the attenuated response
to the H5N1 vaccine. We conclude that seasonal influenza vaccines stimulate
CLRs, implicating a novel role for CLRs in influenza vaccination, whereas the
H5N1 vaccine binds to CLRs but does not initiate an immune response.
The second study compared the immune response to the H5N1 vaccine
with and without the addition of an alum adjuvant; studies were also performed to
determine a mechanism of action for alum in our model of vaccination. We
conclude that alum increases antigen uptake and intracellular processing. While
the alum adjuvant is able to rescue the immunogenicity of the H5N1 vaccine, it
does so though a different mechanism of activation than that employed by
seasonal influenza vaccines.
The development of vaccines for use against HPAI is a high priority,
especially in affected countries, and there are many challenges concerning the
development of pandemic influenza vaccines targeting HPAI. For example, the
amount of vaccine that can be generated globally is limited and would be
insufficient for complete coverage of the world’s population [14, 15]. Additionally,
vaccine production capabilities are concentrated in industrialized countries, and it
is estimated that deaths associated with an influenza pandemic will be greater in
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developing countries than in industrialized countries due to factors such as: lack
of access to adequate medical care; poor public health infrastructures; social
factors such as population density and housing conditions; and host factors such
as poor nutrition and co-existing medical conditions like HIV/AIDS [15].
Furthermore, it is not possible to predict which subtype of influenza will cause the
next pandemic, so a vaccine stockpiled against H5N1 may not protect against an
outbreak of H7N9 [16]. The production of a vaccine following the identification of
a virus causing a pandemic is time consuming, and conventional methods used
for growing the virus for the vaccine strain may not be sufficient as HPAI viruses
are difficult to grow in eggs [14, 17]. Finally, the low immunogenicity produced by
current HPAI pandemic vaccines demonstrates a necessity for multiple
vaccinations, or the addition of an adjuvant, in order to provide protection [14, 18,
19]. A greater understanding behind the immunological mechanisms of influenza
vaccination will lead to the development of more effective vaccines, and will help
to overcome one of the challenges facing pandemic HPAI vaccine development.
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APPENDIX A
Results
Development of cross-protective neutralizing antibodies
One challenge facing the development of vaccines targeting HPAI is that a
vaccine developed which is specific to the virus circulating at the time, such as
the H5N1 vaccine targeting VN1203 developed in 2003/2004, may not provide
protection to a different strain of HPAI that circulates in the future, such as the
H7N9 HPAI virus that began circulating in February 2013, or even a different
strain of H5N1. Studies were conducted to determine whether mice vaccinated
with the adjuvanted H5N1 vaccine targeting VN1203 developed cross-protective
neutralizing antibodies against other strains of H5N1. Sera from BALB/c mice
vaccinated with the adjuvanted H5N1 vaccine, which produced neutralizing
antibodies against VN1203, were tested for the ability to neutralize other H5N1
viruses, specifically: the clade 0 viruses A/Hong Kong/156/1997 (HK156),
A/Hong Kong/483/1997 (HK483), and A/Hong Kong/486/1997; the clade 1 virus
A/Vietnam/1194/2004 (VN1194); and the clade 2 viruses
A/duck/Hunan/795/2002 (DH795) and A/common magpie/Hong Kong/645/2006
(CM645). Briefly, six to eight-week-old BALB/c mice received either a primary or
a primary and secondary vaccination of the adjuvanted H5N1 vaccine with doses
ranging from 0.6ug to 30ug. Secondary vaccinations occurred three weeks
following primary vaccinations. Sera were collected three weeks following
primary vaccination or four weeks following secondary vaccination and assessed
for neutralizing antibodies using a neutralization assay. Sera from two of three
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mice tested against HK156 and HK486 contained neutralizing antibody titers
greater than 1:40, and sera from one of three mice tested against HK483
contained neutralizing antibody titers greater than 1:40. Sera from three of three
mice tested against VN1194, DH795, and CM645 contained neutralizing
antibodies greater than 1:40 (Figure A1). This data demonstrates that mice
vaccinated against VN1203 produced cross-protective neutralizing antibodies
against other strains of H5N1.

Antigen presenting cell migration following influenza vaccination in vivo
The mechanisms surrounding APC activation by inactivated influenza
subunit vaccines presented in the body of this work were elucidated in vitro.
Preliminary studies analyzing APC activation in vivo were also conducted. To
determine the main APC type responding to influenza vaccination in vivo, six to
eight-week-old BALB/c mice (n = 1 per treatment per time point) were vaccinated
subcutaneously (SC) in the inguinal area with either the seasonal or nonadjuvanted HPAI vaccine with or without the addition of a 1:10 dilution of FITC+
FluoSpheres. DCs and macrophages expressing FITC were considered to have
internalized vaccine antigen. Popliteal lymph nodes were harvested 24 or 48
hours following vaccination and assessed for the quantity of DCs and
macrophages present therein. DCs were identified as CD11c+ /CD11b+, and
macrophages were identified as CD11c+/F4/80+ using flow cytometry. Following
vaccination with either the seasonal or non-adjuvanted HPAI vaccines with the
addition of FITC+ FluoSpheres, a larger number of total and FITC+ DCs was
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found in the draining lymph node (DLN) compared to macrophages (Figure A2a
and c). The results also demonstrated that a larger number of DCs may be
responding to the seasonal vaccine compared to the HPAI vaccine. Additionally,
an increased quantity of total and FITC+ DCs was present in the DLN 24 hours
following vaccination compared to 48 hours following vaccination (Figure A2b
and d). These data suggest that DCs are the primary APCs responding to
influenza vaccination, and that 24 hours is the better time point at which to
analyze APC activity in the DLN.
In the experiment discussed above, the majority of cells isolated from the
DLN at 24 hours following vaccination with either the seasonal or non-adjuvanted
HPAI vaccine expressed FITC (Figure A3). Interestingly, 48 hours following
vaccination, a much larger FITC negative cell population was present in the DLN
of mice vaccinated with the seasonal vaccine compared to mice vaccinated with
the non-adjuvanted HPAI vaccine. In the DLN of mice that received the nonadjuvanted HPAI vaccine, there remained a larger number of FITC+ cells
compared to mice that received the seasonal vaccine. This data suggests that 48
hours following vaccination, in mice treated with the seasonal vaccine, APCs
have presented antigen to T cells and T cells are clonally expanding. However, a
limitation to this study is that T cell markers were not utilized, so this conclusion
is only speculation at this time and needs follow-up.
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Antigen presenting cell activation in vivo
To further examine APC activation in vivo, expression of the costimulatory molecules CD40 and CD86 on DCs harvested from the popliteal
lymph node was assessed. BALB/c mice (n = 3 per treatment) were vaccinated
intramuscularly (IM) with either the seasonal or non-adjuvanted H5N1 vaccine.
Popliteal lymph nodes were harvested 24 hours following vaccination and
expression of the co-stimulatory molecules CD40 and CD86 was assessed by
flow cytometry. DCs were identified as CD11c/CD11b positive. Significantly
higher levels of CD40 (Figure A4a) and CD86 (Figure A4b) were detected on
DCs isolated from mice that received the seasonal vaccine compared to mice
that received the non-adjuvanted HPAI vaccine. These data demonstrate that the
seasonal vaccine is able to more efficiently activate APCs in vivo compared to
the non-adjuvanted HPAI vaccine. Interestingly, when comparing cell counts, the
number of DCs present in the DLN did not vary between treatment groups as
seen in Figure A2 (data not shown). This could be due to the difference in the
route of immunization (IM vs. SC).

T cell responses in vivo
Preliminary studies assessed early T cell responses in vivo. BALB/c mice
(n = 2 per treatment) were vaccinated SC in the inguinal area with either the
inactivated subunit vaccine targeting the 2009 H1N1 pandemic virus or the nonadjuvanted HPAI vaccine. Popliteal lymph nodes were harvested 24 hours
following vaccination and assessed for a CD28-/CD62L+ homing T cell
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population. In the DLNs harvested from mice that received the 2009 H1N1
vaccine, a CD28-/CD62L+ homing T cell population was detected, whereas in
mice that received the non-adjuvanted HPAI vaccine, this cell population was not
detected (Figure A5). This data suggests differences in T cell responses to the
2009 H1N1 vaccine when compared to the non-adjuvanted HPAI vaccine.
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Figure Legends
Figure A1. Cross-protective neutralizing antibodies in BALB/c mice. BALB/c
mice received either a primary or a primary and secondary vaccination of the
adjuvanted HPAI vaccine targeting VN1203. Sera were collected three weeks
following primary vaccination or four weeks following secondary vaccination and
neutralizing antibody titers to other strains of H5N1 were determined utilizing
neutralization assays. The viruses analyzed include: HK156 (closed circles);
HK483 (squares); HK486 (triangles); VN1194 (upside-down triangles); DH795
(diamonds); and CM645 (open circles). Data points represent individual animals.

Figure A2. DCs respond to influenza vaccine antigen in vivo. BALB/c mice
received a SC vaccination of either the seasonal or non-adjuvanted HPAI
vaccine with or without the addition of FITC+ FluoSpheres. Popliteal lymph nodes
were harvested 24 or 48 hours following vaccination and assessed for
CD11c+/CD11b+ DC and CD11c+/F4/80+ macrophage populations by flow
cytometry. A and B. Cell counts in the DLN following vaccination with either the
seasonal vaccine (white bars) or non-adjuvanted HPAI vaccine (black bars) at 24
and 48 hours respectively. C and D. Cell counts representing FITC+ APCs in the
DLN following vaccination with seasonal vaccine (white bars) or non-adjuvanted
HPAI vaccine (black bars) mixed with FITC+ FluoSpheres at 24 and 48 hours
respectively. The mice utilized in this experiment were separate from those in A
and B.
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Figure A3. Increased FITC negative cell population present in the DLN
following seasonal vaccination. BALB/c mice received a SC vaccination of
either the seasonal or non-adjuvanted HPAI vaccine with the addition of FITC+
FluoSpheres. Popliteal lymph nodes were harvested 24 or 48 hours following
vaccination and cells were assessed for the presence or absence of FITC+
expression by flow cytometry.

Figure A4. Increased expression of co-stimulatory molecules on DCs
treated with seasonal influenza vaccine. BALB/c mice were vaccinated
intramuscularly with either the seasonal vaccine or non-adjuvanted HPAI
vaccine. Popliteal lymph nodes were harvested 24 hours following vaccination
and CD11c+/CD11b+ DCs were assessed for the expression of co-stimulatory
markers by flow cytometry. A. Median fluorescence intensity (MFI) of CD40
expression on DCs isolated from the DLNs of mice vaccinated with the seasonal
influenza vaccine (white bars) or non-adjuvanted HPAI vaccine (black bars).
Error bars indicate mean ± SEM (*p<.05, Student’s t-test). B. Median
fluorescence intensity (MFI) of CD86 expression on DCs isolated from the DLNs
of mice vaccinated with the seasonal influenza vaccine (white bars) or nonadjuvanted HPAI vaccine (black bars). Error bars indicate mean ± SEM (*p<.05,
Student’s t-test).

Figure A5. CD28-/CD62L+ homing T cell population present in the DLN of
mice treated with seasonal but not HPAI vaccine. BALB/c mice were
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vaccinated subcutaneously with either the 2009 H1N1 pandemic vaccine or the
non-adjuvanted HPAI vaccine. Popliteal lymph nodes were harvested 24 hours
following vaccination and cell populations were assessed by flow cytometry for
CD28-/CD62L+ homing T cells. Cells were gated on CD28- cell populations
followed by expression of CD62L.
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